Infusion system, device, and method having advanced infusion features

Information

  • Patent Grant
  • 12115337
  • Patent Number
    12,115,337
  • Date Filed
    Monday, November 30, 2020
    3 years ago
  • Date Issued
    Tuesday, October 15, 2024
    a month ago
Abstract
Aspects of the present disclosure provide systems, devices, and methods for delivering substances such as fluids, solutions, medications, and drugs to patients using infusion devices having a set of advanced features. These advanced features include aspects related to the programming of infusion devices, the configuration of infusion sequences performed by the infusion devices, and the interconnection of multiple infusion devices for interoperation during an infusion having a sequence of infusion steps.
Description
TECHNICAL FIELD

The present application is generally related to the automated administration of a medication therapy. More particularly, the present application is directed toward configuring and managing delivery of medications in systems and methods that include infusion devices.


BACKGROUND

Modern medical devices, including infusion devices, are increasingly being controlled by microprocessor based systems to deliver substances such as fluids, solutions, medications, and drugs to patients. A typical control for an infusion device includes a user interface enabling a medical practitioner to enter a dosage of fluid to be delivered, the rate of fluid delivery, the duration, and the volume of a fluid to be infused into a patient. To deliver medications to the patient, an infusion device typically includes a pump and a fluid delivery device such as a syringe, tubing, section of tubing, or cassette.


Existing infusion devices, however, might be limited in various ways. As one example, while multi-channel infusion devices might be able to deliver multiple medications to a patient, these infusion devices might be limited in the number of medications they can deliver and in their ability to interoperate with other infusion devices of different types. As a result, existing infusion devices might not be suitable or even capable of providing complex medication therapies involving multiple medications delivered in particular sequences. Therefore a need exists for advanced systems and devices for delivering substances to patients.





BRIEF DESCRIPTION OF THE DRAWINGS

Aspects of the disclosure may be implemented in certain parts, steps, and embodiments that will be described in detail in the following description and illustrated in the accompanying drawings in which like reference numerals indicate similar elements. It will be appreciated with the benefit of this disclosure that the steps illustrated in the accompanying figures may be performed in other than the recited order and that one or more of the steps may be optional. It will also be appreciated with the benefit of this disclosure that one or more components illustrated in the accompanying figures may be positioned in other than the disclosed arrangement and that one or more of the components illustrated may be optional. Furthermore a set of elements is intended to include one or more elements.



FIG. 1 depicts a schematic diagram of an example medication management system including an example medical management unit and an example medical device.



FIG. 2 depicts a schematic diagram of an example medical device.



FIG. 3 depicts an example of a single-channel infusion device.



FIG. 4 depicts an example of a multi-channel infusion device.



FIG. 5 depicts an example of a medical device including two infusion devices that are associated with one another.



FIG. 6 depicts an example of a cassette kit for an infusion device.



FIG. 7 depicts an example user interface of an infusion device having multiple lines.



FIG. 8 depicts a flowchart of example method steps for programming an infusion to be delivered by an infusion device having multiple lines.



FIG. 9 depicts an example user interface at which the caregiver selects the substance to be delivered during the continuous infusion.



FIG. 10 depicts an example user interface at which the caregiver selects the concentration at which the selected substance should be delivered during the continuous infusion.



FIG. 11 depicts an example user interface at which the caregiver selects the dose and unit for the continuous infusion.



FIG. 12 depicts an example user interface at which the caregiver specifies the value of the dose per unit for the continuous infusion.



FIG. 13 depicts an example user interface where the caregiver has selected to specify a VTBI.



FIG. 14 depicts an example user interface at which the caregiver selects the action the infusion device should perform upon completing the continuous infusion.



FIG. 15 depicts an example user interface that displays the parameters of the primary infusion currently being delivered by the infusion device.



FIG. 16 depicts an example user interface at which the caregiver may specify the action to perform upon completion of a piggyback infusion.



FIG. 17 depicts an example user interface that displays the parameters of both the primary and secondary infusions currently being delivered by the infusion device.



FIGS. 18A-18B depict a flowchart of example method steps for selecting a medication.



FIGS. 19A-19B depict a flowchart of example method steps for performing a safety check for duplicate infusion substances.



FIGS. 20A-20B depict a flowchart of example method steps for performing a safety check for compatible infusion substances.



FIGS. 21A-21B depict a flowchart of example method steps for specifying a dose for the selected substance at the infusion device.



FIG. 22 depicts a flowchart of example method steps for specifying a VTBI.



FIG. 23 depicts a flowchart of example method steps for confirming an infusion configured at the infusion device.



FIG. 24 depicts a flowchart of example method steps for converting a current continuous infusion to one of the various advanced infusion types.



FIG. 25 depicts an example user interface of an infusion device at which the caregiver may add a step to an infusion sequence at the infusion device.



FIGS. 26A-26B depict a flowchart of example method steps for adding a new step to a current infusion sequence at an infusion device.



FIG. 27 depicts an example user interface of an infusion device for changing the line for an inter-channel sequencing infusion.



FIG. 28 depicts a flowchart of example method steps for ganging infusion devices.



FIG. 29 depicts a flowchart of example method steps for viewing and manipulating the list of infusion steps configured for an infusion sequence.



FIG. 30 depicts an example user interface displaying a list of infusion sequence steps for an infusion to be delivered by an infusion device.



FIG. 31 depicts an example user interface of an infusion device for displaying the parameters associated with a step the caregiver has selected in the list of infusion steps.



FIG. 32 depicts the user interface of FIG. 30 in which the caregiver has selected one of the steps (step no. 4) in the list of infusion steps.



FIG. 33 depicts the user interface of FIG. 32 in which the caregiver has dragged the selected step to the right to remove it from the list.



FIG. 34 depicts a flowchart of example method steps for converting a continuous infusion to an intermittent infusion.



FIG. 35 depicts a flowchart of example method steps for specifying one or more callback options.



FIG. 36 depicts an example user interface for cloning a current step of an intermittent infusion.



FIG. 37 depicts a flowchart of example methods steps for configuring an intermittent infusion.



FIG. 38 depicts a flowchart of example method steps for converting a continuous infusion to an “infinite” flow infusion and configuring the “infinite” flow infusion.



FIG. 39 depicts a flowchart of example method steps for configuring an “infinite” flow infusion.



FIGS. 40A-40B depict a flowchart of example method steps for an “infinite” flow infusion.



FIG. 41A depicts an example user interface of an infusion device during an “infinite” infusion flow.



FIG. 41B depicts another example user interface of an infusion device during an “infinite” infusion flow.



FIGS. 42A-42B depict a flowchart of example method steps for selecting a secondary infusion at an infusion device.



FIG. 43 depicts an example user interface of an infusion device at which a caregiver may select to configure an advanced infusion type.



FIG. 44 depicts a flowchart of example method steps for selecting an advanced infusion type to configure at an infusion device.



FIG. 45 depicts a flowchart of example method steps for configuring a TPN infusion at an infusion device.



FIG. 46 depicts a flowchart of example method steps for selecting a TPN protocol at an infusion device.



FIG. 47 depicts a flowchart of example method steps for configuring a multi-step infusion at an infusion device.



FIG. 48 depicts a flowchart of example method steps for configuring an inter-channel sequencing infusion.



FIG. 49 depicts a flowchart of example method steps for selecting a pre-defined inter-channel sequencing protocol.



FIG. 50 depicts an example user interface for selecting an inter-channel sequencing protocol at an infusion device.



FIG. 51 depicts a flowchart of example method steps for performing safety checks based on a selected inter-channel sequencing protocol.



FIG. 52 depicts an example user interface of an infusion device for listing and selecting infusion devices to be used in an inter-channel sequencing infusion.



FIG. 53 depicts an example user interface of an infusion device displaying a confirmation request to gang the infusion device to another infusion device.



FIG. 54 depicts a user interface of an infusion device for assigning infusion lines to steps of an inter-channel sequencing infusion.



FIG. 55 depicts a flowchart of example method steps for configuring the steps of an inter-channel sequencing infusion.



FIG. 56A depicts a user interfaces that include a visual indicator to identify the infusion device as a master or slave infusion device.



FIG. 56B depicts another user interfaces that include a visual indicator to identify the infusion device as a master or slave infusion device.



FIG. 57 depicts an example of a possible inter-channel sequencing infusion that may be implemented utilizing the infusion devices described herein.



FIG. 58 depicts a flowchart of example method steps for configuring the steps of an inter-channel sequencing infusion manually.



FIG. 59 depicts a user interface for configuring the first delivery of the second step of an inter-channel sequencing infusion.



FIG. 60 depicts a user interface for configuring the second delivery of the sixth step of an inter-channel sequencing infusion.



FIG. 61 depicts an example user interface of an infusion device for notifying or warning a caregiver regarding a non-delivery condition.



FIG. 62 depicts a flowchart of example method steps for configuring a piggyback infusion at an infusion device.



FIG. 63 depicts a flowchart of example method steps for configuring piggyback infusion options including selecting or specifying an action to perform at the end of the piggyback infusion.



FIG. 64 depicts a flowchart of example method steps for configuring a concurrent infusion.



FIG. 65 depicts an example of an implementation of an infusion device.



FIG. 66 depicts an example of a set of interconnected infusion devices.



FIG. 67 depicts interconnected infusion devices respectively associated with patients.



FIG. 68 depicts a flowchart of example method steps for ganging together infusion devices via a medication management system.



FIG. 69 depicts a flowchart of example method steps for ganging together infusion devices via direct communications.



FIG. 70 depicts a flowchart of example method steps for designating a master infusion device for infusion devices ganged together via an interconnecting device.



FIG. 71 depicts a flowchart of example method steps for designating a master infusion device for infusion devices ganged together via wireless communications.



FIGS. 72A-72B depict example steps of another method for ganging together infusion devices that are interconnected via a medication management system.



FIG. 73 depicts a flowchart of example method steps for configuring an infusion at an infusion device.



FIG. 74 depicts a flowchart of example method steps for configuring a sequence of infusion steps at an infusion device.



FIG. 75 depicts a flowchart of example method steps for interconnecting multiple infusion devices and controlling the interconnected infusion devices from a master infusion device during an infusion.





DETAILED DESCRIPTION

In general the present disclosure provides systems, devices, and methods for delivering substances such as fluids, solutions, medications, and drugs to patients using infusion devices having a set of advanced features. These advanced features include aspects related to the programming of infusion devices, the configuration of infusion sequences performed by the infusion devices, and the interconnection of multiple infusion devices for interoperation during an infusion having a sequence of infusion steps.


The aspects described herein may be employed using infusion products available from Hospira Worldwide, Inc. (“Hospira”) headquartered in Lake Forest, Ill. Examples of infusion systems that may be utilized include the Plum A+™ Infusion System and the Plum A+3™ Infusion System available from Hospira. The infusion systems may utilize the PlumSet™ cassette also available from Hospira. The cassette may be a dual-input cassette with two input ports from respective delivery sources and one output port to the patient. The deliver source may be, e.g., a bottle, bag, or other type of container suitable for infusion procedures. The dual-input cassette thus provides the ability to deliver two infusions to the patient via the same infusion channel. The dual-input cassette thus provides opportunities to provide infusion systems, devices, and methods with advanced infusion features.


As described in further detail below, infusion systems, devices, and methods may include the following advanced infusion features. One advanced infusion feature allows a caregiver to dynamically configure the parameters of a current ongoing infusion as well as add steps to a current ongoing infusion. This advanced infusion feature advantageously allows the caregiver to convert the current infusion type to another type of infusion. This advanced infusion feature also advantageously allows the caregiver to initiate the first step of an infusion while configuring the subsequent steps of the infusion. As described in further detail below, an infusion device may provide a user interface that allows a caregiver to select and configure infusion steps, e.g., selecting the infusion type and infusion parameters, arranging the sequence of infusion steps, and confirming individual infusion steps and the overall infusion sequence.


Another advanced infusion feature interconnects multiple infusion devices via a network in a master/slave configuration. This feature provides protocols for discovering interconnected infusion devices available for selection, designating an infusion device as the master infusion device, and selecting one or more slave infusion devices. As described in further detail below, different techniques may be employed to designate the master infusion device and select the slave infusion devices depending on whether the infusion devices are interconnected via a physical or wireless connection. This feature also provides protocols for designating a new master infusion device if the slave infusion devices lose the connection with the current master infusion device.


The master/slave configuration of the infusion devices allows for advanced infusion features related to inter-channel and inter-device sequencing of infusion steps. As also described in further detail below, a caregiver may program infusion steps between different types of infusion devices may program infusion steps with multiple deliveries via multiple channels per step. In this way, the advanced infusion features allow the caregiver to configure complex sequences of infusion steps involving multiple delivery sources, multiple infusion devices, and multiple channels.


Interconnecting the infusion devices also provides various safety features. As one example, the total infusion rate across all infusion devices associated with a patient may be limited. As another example, the total amount of air accumulated across all infusion devices associated with the patient may be tracked, and an alarm may be provided to a caregiver if the total amount of accumulated air reaches a predetermined threshold. In a further example, duplication and compatibility safety checks for multiple infusion devices connected to the same access site, and a notification indicating duplicate or incompatible substances may be provided to a caregiver who may have the ability to review and override any conflicts.


These and additional aspects will be appreciated with the benefit of the disclosures provided in further detail below.


Medication Management Systems, Medical Managements Units, and Medical Devices

As a brief introduction to the aspects discussed in further detail below, the following description of medication management systems, medical management units and medical devices is provided.



FIG. 1 depicts an example medication management system including an example medical management unit and an example medical device. The medication management system (MMS) 10 includes a medication management unit (MMU) 12 and a medical device 14, typically operating in conjunction with one or more information systems or components of a hospital environment 16. The term hospital environment should be construed broadly herein to mean any medical care facility, including but not limited to a hospital, treatment center, clinic, doctor's office, day surgery center, hospice, nursing home, and any of the above associated with a home care environment. There can be a variety of information systems in a hospital environment. As shown in FIG. 1, the MMU 12 communicates to a hospital information system (HIS) 18 via a caching mechanism 20 that is part of the hospital environment 16.


The caching mechanism 20 is primarily a pass through device for facilitating communication with the HIS 18 and its functions can be eliminated or incorporated into the MMU 12 and/or the medical device 14 and/or the HIS 18 and/or other information systems or components within the hospital environment 16. The caching mechanism 20 provides temporary storage of hospital information data separate from the HIS 18, the medication administration record system (MAR) 22, pharmacy information system (PhIS) 24, physician order entry (POE) 26, and/or Lab System 28. The caching mechanism 20 provides information storage accessible to the MMS 10 to support scenarios where direct access to data within the hospital environment 16 is not available or not desired. For example, the caching mechanism 20 provides continued flow of information in and out of the MMU 12 in instances where the HIS 18 is down or the connectivity between the MMU 12 and an electronic network is down.


The HIS 18 communicates with a MAR 22 for maintaining medication records and a PhIS 24 for delivering drug orders to the HIS. A POE device 26 permits a healthcare provider to deliver a medication order prescribed for a patient to the hospital information system directly or indirectly via the PhIS 24. A medication order can be sent to the MMU 12 directly from the PhIS 24 or POE device 26. As used herein the term medication order is defined as an order to administer something that has a physiological impact on a person or animal, including but not limited to liquid or gaseous fluids, drugs or medicines, liquid nutritional products and combinations thereof.


Lab system 28 and monitoring device 30 also communicate with the MMU 12 to deliver updated patient-specific information to the MMU 12. As shown, the MMU 12 communicates directly to the lab system 28 and monitoring device 30. However the MMU 12 can communicate to the lab system 28 and monitoring device 30 indirectly via the HIS 18, the caching mechanism 20, the medical device 14 or some other intermediary device or system.


Delivery information input device 32 also communicates with the MMU 12 to assist in processing drug orders for delivery through the MMU 12. The delivery information input device 32 can be any sort of data input means, including those adapted to read machine readable indicia such as barcode labels; for example a personal digital assistant (PDA) with a barcode scanner. Hereinafter the delivery information input device 32 will be referred to as input device 32. Alternatively, the machine readable indicia may be in other known forms, such as radio frequency identification (RFID) tag, two-dimensional bar code, ID matrix, transmitted radio ID code, human biometric data such as fingerprints, etc. and the input device 32 adapted to “read” or recognize such indicia. The input device 32 is shown as a separate device from the medical device 14; alternatively, the input device 32 communicates directly with the medical device 14 or may be integrated wholly or in part with the medical device.


With reference to FIG. 2, an electronic network 114 connects the MMU 12, medical device 14, and hospital environment 16 for electronic communication. The electronic network 114 can be a completely wireless network, a completely hard wired network, or some combination thereof.



FIG. 2 is a schematic diagram illustrating several functional components of a medical device 14 for implementing aspects of the present disclosure. The device 14 includes many more components than those shown in FIG. 4. However, it is not necessary that all these components be shown in order to disclose an illustrative embodiment for practicing aspects of the present disclosure.


In the context of the present disclosure, the term “medical device” includes without limitation a device that acts upon a cassette, reservoir, vial, syringe, or tubing to convey medication or fluid to or from a patient (for example, an enteral pump, a parenteral infusion pump, a patient controlled analgesia (PCA) or pain management medication pump, or a suction pump), a monitor for monitoring patient vital signs or other parameters, or a diagnostic, testing or sampling device.


For the purpose of exemplary illustration only, the medical device 14 is disclosed as an infusion pump. More particularly, the medical device 14 can be a single channel infusion pump, a multi-channel infusion pump (as shown), or some combination thereof.


The medical device 14 in FIG. 2 is a pump-style medical device and includes a network interface 112 for connecting the medical device 14 to electronic network 114. Where a wireless connection to the electronic network 114 is desired, network interface 112 operates an antenna for wireless connection to the electronic network 114. The antenna can project outside the device 14 or be enclosed within the housing of the device.


A processor 118 is included in the medical device 14 and performs various operations described in greater detail below. The input/output device 120 allows the caregiver to receive output from the medical device 14 and/or input information into the medical device 14. The input/output device 120 may be provided as a single device such as a touch screen 122, or as a separate display device and a separate input device. The display screen 122 of the medical pump 14 may be a thin film transistor active matrix color liquid crystal display with a multi-wire touch screen. A membrane generally impermeable to fluids may overlay the display screen 122 so the caregiver can press on images of keys or buttons on the underlying screen with wet gloves, dry gloves or without gloves to trigger an input.


A memory 124 communicates with the processor 118 and stores code and data necessary for the processor 118 to perform the functions of the medical device 14. More specifically, the memory 124 stores multiple programs formed in accordance with the present disclosure for various functions of the medical device 14 including a graphical user interface program 126 with multiple subparts described in greater detail below.


Infusion and Infusion Devices

Infusion devices may be programmed to carry out various types of infusion sequences. Types of infusion sequences include continuous infusion, intermittent infusion, multi-step infusion, inter-channel sequencing infusion, “infinite” (i.e., uninterrupted) flow infusion, and total parenteral nutrition (TPN) infusion.


Continuous infusion refers to infusion that occurs at a defined infusion rate until the infusion device has delivered the Volume-to-be-Infused (VTBI). The infusion device may then perform a user-selectable action which may include, e.g., keeping the vein open (KVO), continuing the infusion rate, or stopping the infusion.


Intermittent infusion refers to infusion that occurs until the infusion device has delivered the VTBI, at which point the infusion device performs a user-selectable action and then resumes the infusion until infusion device has again delivered the VTBI. The infusion device may repeat an intermittent infusion a user-specified number of times.


Multi-step infusion is similar to intermittent infusion as multi-step infusion involves multiple sequential infusions of the same medication. In contrast to intermittent infusion, however, subsequent infusions in multi-step infusion may be configured to deliver the medication at a different dose, rate, VTBI, or duration. A subsequent infusion in a multi-step infusion may also be configured such that a different action is performed when the subsequent infusion is complete.


Inter-channel sequencing infusion refers to infusion that involves multiple sequential infusions that can be delivered via different lines and thus from different sources containing different substances. The infusion devices used for inter-channel sequencing may include a single-channel large volume pump (LVP), a dual-channel LVP, a syringe pump, or a patient-controlled analgesia (PCA) pump. Inter-channel sequencing infusion may also be performed using multiple infusion devices in which a channel of a first infusion device infuses a first substance and a channel of a second infusion device infuses a second substance. Inter-channel sequencing infusion that uses multiple infusion devices may be referred to as inter-device infusion.


“Infinite” flow infusion refers to infusion that utilizes two delivery lines on a single cassette channel wherein the infusion device automatically switches to the other line when the current line completes its infusion such that there is no interruption in the delivery. A caregiver may then replace the depleted delivery source without having to stop or otherwise interrupt the current infusion.


Total parenteral nutrition infusion refers to infusion that delivers nutrition intravenously according to a pre-defined protocol.


As noted above, multi-channel infusion devices may include both a primary and a secondary line. A caregiver may program the infusion device to deliver a primary infusion via either the primary or the secondary line. When an infusion device has been programmed with a primary infusion, the caregiver may program the other line (either the primary line or the secondary line) to deliver a secondary infusion. The secondary infusion may be a concurrent infusion or a piggyback infusion. A concurrent infusion refers to simultaneous delivery from two delivery sources and independent infusion rates. Piggyback infusion refers to infusion that will stop infusion on one line, complete infusion on another line, and then restart infusion on the stopped line.


As also noted above a medical device can be a single channel infusion pump, a multi-channel infusion pump, or some combination thereof.



FIG. 3 depicts an example of a medical device that is a single channel infusion device. The infusion device may include a display screen that may display error messages, error codes, and suggested actions. The infusion device may comprise a memory, a processor, a clock (real time or otherwise) and other components. The memory may store computer-executable instructions the processor may execute to cause the infusion device to perform one or more steps described in further detail below.



FIG. 4 depicts an example of a medical device 14 that is a multi-channel infusion device having a first channel 132 with first channel machine-readable label 134 and a second channel 136 with a second channel machine-readable label 138. A user of the medical device 14 operates the machine-readable input device 130 to select a channel from one or more channels 132 and 136, by scanning in the associated machine-readable label 134 or 138.


The caregiver selects the desired channel 132 or 136 by using the machine-readable input device 130 to scan a factory or hospital programmed, unique, machine-readable label 134 or 138 that is electronically generated and presented on the screen 122, which may be juxtapositioned near the respective channel 132 or 136. Alternatively, the machine-readable labels 134 and 138 are physically affixed to the medical device 14, which may be on or juxtapositioned near the channel 132 and 136, respectively. Since the machine-readable labels 134 and 138 are generated and/or can be stored in memory 124 by the medical device 14, the medical device 14 can associate the machine-readable labels 134 and 138 to the channels 132 or 136. The medical device 14 then allows the caregiver to program and activate the selected channel 132 or 136. The caregiver may also manually select the desired channel by touching an appropriate folder tab on the touch screen. The folder tabs are labeled and/or physically arranged on the screen so as to be proximate to the corresponding channel 132 or 136.


In a further aspect of the wireless embodiment, the medical devices can periodically broadcast a unique wireless device/channel IP address and/or a self-generated unique machine-readable label (for example, a barcode) 134 or 138 that can also be presented on the screen 122. Alternatively, the machine-readable labels 134 and 138 are physically affixed to or posted on the medical device 14. Each medical device may correlate such broadcasted or posted device/channel IP addresses and/or barcodes with a particular patient, who is also identified by a unique machine readable label (not shown) or patient IP address. The caregiver associates the desired pump(s) or channel(s) 132, 136 with the patient by using the machine-readable input device 130 to scan the unique machine-readable labels 134, 138 and the patient's machine readable label. This causes the appropriate pump processor(s) 118 to associate the appropriate pump channel(s) 132, 136 with the patient. Then the pumps or channels can associate communicate, and coordinate with each other wirelessly.


The medical device 14 includes a split touch screen 122 having a first channel screen portion 140 associated with first channel 132 and a second channel screen portion 142 associated with the second channel 136. Each channel screen portion 140 and 142 presents a subset of the delivery information regarding the respective channels 132 or 136, including without limitation therapeutic agent name, concentration, dose rate, VTBI, and alarm information, in a font size that it is easily readable by a caregiver from a distance such as, for example, from approximately fifteen to twenty feet (4.6-6.2 meters) away. This is what is referred to as a “far view” delivery screen. The far view delivery screens display subsets of the information found on the relevant “near view” delivery screens. The near view delivery screen displays drug name, concentration, dose rate, time remaining, VTBI, volume remaining, and alarm name for the highest priority alarm if in an alarm state. The near view delivery screen will switch to the far view delivery screen after a defined period of time that is predetermined by the manufacturer, configurable by the facility via the drug library, and/or set by the caregiver at the device, for example after 20 seconds.


Upon a caregiver touching one of the tabs “A” or “B” or anywhere on the channel screen portions 140 or 142 of the far view delivery screen, a “near view” delivery screen is presented on the screen 122. The channel screen portion 140 or 142 selected or corresponding to the tab selected expands in area but the size of at least some of the text therein is shrunk.


The shrinkage of one of the channel screen portions 140 and 142 and enlargement of its counterpart provides additional space for one or more data display or data entry fields to be placed on screen 122. As discussed below, data displays or data entry fields are placed on screen 122 in space previously occupied by portions of the channel screen portion 140 or 142. This reallocation of space on screen 122 permits the caregiver to enter inputs more easily since the data entry field can be large, preferably at least as large or, more preferably, larger in area than the original channel screen portions 140 and 142 were in the delivery screen mode. Additionally, the reallocation of space on screen 122 provides greater space for presenting information on the channel being adjusted or monitored.


Referring again to FIG. 4, the medical device 14 includes dedicated or fixed tactile infuser buttons, and images of buttons on the LCD-touch screen 122. The fixed tactile buttons 133, 135, 137, and 139 provide the following functions: LOAD/EJECT button 133—opens and closes the cassette carriage; ON/OFF button 135—turns power on and off; ALARM SILENCE button 137—silences a silenceable alarm for a specified period of time, for example two minutes; and EMERGENCY STOP button 139—stops all channels.


The LCD color touch screen 122 allows the caregiver to access and use on-screen button images, for example 3D button images, and data entry fields. The touch screen 122 uses a membrane over the LCD display so a single keypress does not cause significant infusion pole movement nor is it mistaken for a double keypress. The touch screen also accommodates a keypress whether the caregiver is wearing wet gloves, dry gloves, or no gloves.



FIG. 5 depicts an example medical device 11 that includes a single-channel infusion device 11A and a multi-channel infusion device 11B. The single-channel infusion device 11A has a single channel 51 (i.e., an “A” channel). The multi-channel infusion device has a first channel 33 (i.e., a “B” channel) and a second channel 39 (i.e., a “C” channel). The single channel infusion device 11A and the multi-channel infusion device 11B are physically and communicatively connected to each other for programming and operation in a coordinated manner. In one example, the single channel infusion device 11A and the multi-channel infusion device 11B are detachably coupled together. Although FIG. 5 illustrates a single channel medical device 11A associated with a multi-channel medical device 11B, is it noted that this is for illustrative purposes only, and other various combinations of various types of infusion devices may be made without departing from the present disclosure. Additionally, while the infusion devices 11A and 11B are shown as being physically associated, it is contemplated that they may alternatively be wirelessly associated.


The infusion device 11B of the medical device 11 has a first channel 33 and a second channel 39. A first tube set may be operably coupled to the first channel 33 to deliver a fluid from the first channel 33 and a second tube set may be operably coupled to the second channel 39 to deliver a fluid from the second channel 39. Each of the channels 33, 39 includes a respective pumping mechanism 35, 37 for acting upon a tube set to pump fluid. Various pumping mechanisms may be utilized without detracting from the present invention. The tube set may be made of soft, kink-resistant medical grade tubing and may include a medicinal dispensing pump cassette that is acted upon by the pumping mechanism. The first channel 33 may also include a first channel machine-readable label (134 in FIG. 4) and the second channel 39 may also include a second channel machine-readable label (138 in FIG. 4). A user of the medical device 10 may operate a machine-readable input device (130 in FIG. 4) to select a channel from one or more channels 33 and 39, by scanning in the associated machine-readable label.


The user may select the desired channel 33 or 39 by using the machine-readable input device to scan a factory or hospital programmed, unique, machine-readable label that is electronically generated and presented on the screen 23, which may be juxtapositioned near the respective channel 33 or 39. Alternatively, the machine-readable labels may be physically affixed to the medical device 11, which may be on or juxtapositioned near the channel 33 and 39 respectively. Since the machine-readable labels are generated and/or can be stored in memory by the infusion device 11B, the infusion device 11B can associate the machine-readable labels to the channels 33 or 39. The infusion device 11B then allows the user to program and activate the selected channel 33 or 39. The user may also manually select the desired channel by touching an appropriate folder tab on the touch screen. The folder tabs are labeled and/or physically arranged on the screen so as to be proximate to the corresponding channel 33 or 39. That is, the “B” tab is juxtapositioned near or adjacent to the “B” channel 33 and the “C” tab is juxtapositioned near or adjacent to the “C” channel 39.


A graphical user interface program may reallocate the screen 23 for one of the infusion devices 11A or 11B of the medical device 11. The infusion device 11B includes a split touch screen 23 having a first channel screen portion 41 associated with first channel 33 and a second channel screen portion 43 associated with the second channel 39. Each channel screen portion 41 and 43 presents a subset of the delivery information regarding the respective channels 33 or 39, including without limitation therapeutic agent name, concentration, dose rate, VTBI, and alarm information, in a font size of at least twenty-eight points so that it is easily readable by a user from approximately fifteen to twenty feet (4.6-6.2 meters) away. This is what is referred to as a “far view” delivery screen.


When a user touches one of the tabs “B” or “C,” or any part of the channel screen portions 41 or 43 of the far view delivery screen, a “near view” delivery screen is presented on the screen 23. The channel screen portion 41 or 43 selected or corresponding to the tab selected expands in area but the size of at least some of its text is reduced. The font size for rate and VTBI information on the near view delivery screen is substantially less than twenty-eight points. The other channel screen portion 41 or 43 (if present) is reduced in size, hidden or moved to the background to limit its space on the screen 23. Preferably, if the “B” tab of the first channel screen portion 41 is selected, the “C” tab of the second channel screen portion 43 remains exposed, but is grayed or colored differently to indicate it is not the channel of interest. Thus, the second channel screen portion 43 becomes smaller than the first channel screen portion 41, as the first channel screen portion 41 is currently being viewed and adjusted by the user and is therefore of primary concern. The second or C channel can be selected in a similar manner, whereupon the first channel portion 41 of the screen 23 will become smaller and the second channel portion 43 will become larger. Since the screens for the respective channels are substantially identical, except for the position of their tabs, features shown in the drawings and described below relative to the B channel also apply to the C channel, and vice versa.


As described above, the memory stores multiple programs formed in accordance with the present invention, including an infuser program that allows for inter-channel sequencing infusions. Inter-channel sequencing infusions allows for the sequential delivery of separate substances from two or more channels. In particular, the infuser program can be programmed by a caregiver to sequence dispensation of substances between channels such that a patient can receive substances from two or more channels without having to reprogram the infusion device.



FIG. 6 depicts an example of a cassette kit that may be used in a single-channel or multi-channel infusion device. As seen in FIG. 6, the cassette kit includes a cassette connected to a convertible piercing pin with drip chamber via a primary line along which a slide clamp may be positioned. The cassette is also connected to a patient line that includes a Y-site connector along its length and a protective cap with filter at one end. A roller clamp may also be positioned along the length of the patient line. The cassette in FIG. 6 also includes a secondary inlet port at which a secondary line may be connected.


The cassette in FIG. 6 may advantageously allow two deliver two infusions using the same infusion channel from delivery sources respectively connected to each of its two input ports. The cassette may route the substance received from the delivery sources at the input ports to the output line connected to the patient. As described in further detail below, the use of this type of cassette advantageously presents new opportunities for configuring infusions at an infusion device.


Dynamic Infusion Programming

As noted above, aspects of the disclosure are directed toward advanced infusion features that allow a caregiver to dynamically configure the parameters of a current ongoing infusion of add steps to a current ongoing infusion.



FIG. 7 depicts an example user interface of an infusion device having multiple lines, in this case a primary line (Line A) and a secondary line (Line B). As seen in FIG. 7, the interface includes input elements for selecting a type of infusion to program for the primary line, in this case a continuous infusion or an advanced infusion. Advanced infusions may include, e.g., an intermittent infusion, a multi-step infusion, an inter-channel sequencing infusion, an “infinite” infusion, and a TPN infusion. The interface also includes input elements for selecting a type of infusion to program for the secondary line, in this case a concurrent infusion or a piggyback infusion.



FIG. 8 depicts a flowchart of example method steps for programming an infusion to be delivered by an infusion device having multiple lines. As seen in FIG. 8, if the primary line and the secondary line have not yet been programmed, the caregiver may select either the primary line or the secondary line to program for the primary infusion. For the primary infusion, the caregiver may select either a continuous infusion or an advanced infusion as noted above with reference to FIG. 7. If the caregiver selects to provide an advanced type of infusion, the caregiver may select the particular type of advance infusion desired (e.g., intermittent, multi-step, inter-channel sequencing, “infinite,” or TPN). The caregiver may configure the parameters of the selected infusion type, and, once programmed, the infusion device may initiate the primary infusion.


If either the primary line or the secondary line is already programmed, the caregiver may select the non-programmed line for a secondary infusion. As seen in FIG. 8, if the primary line has been programmed for the primary infusion, then the caregiver may select the secondary line for the secondary infusion. If, however, the secondary line has been programmed for the primary infusion, the caregiver may select the primary line for the secondary infusion. As also seen in FIG. 8, the caregiver may select either a concurrent infusion or a piggyback infusion for the secondary infusion. The caregiver may likewise configure the parameters of the selected infusion type and, once programmed, the infusion device may initiate the secondary infusion.



FIGS. 9-15 depict example user interfaces of an infusion device for configuring the parameters of a continuous infusion on the primary line (e.g., Line A). FIG. 9 depicts an example user interface at which the caregiver selects the substance to be delivered during the continuous infusion. The user interface includes a list of substances available for selection which is filterable by substance name. FIG. 10 depicts an example user interface at which the caregiver selects the concentration at which the selected substance should be delivered during the continuous infusion. The interface includes a list of concentrations available for selection. FIG. 11 depicts an example user interface at which the caregiver selects the dose and unit for the continuous infusion. This interface includes a list of doses per unit available for selection. FIG. 12 depicts an example user interface at which the caregiver specifies the value of the dose per unit for the continuous infusion. This interface includes input elements, in this case a keypad and a slider, at which the caregiver may specify the desired value for the dose per unit.


For a continuous infusion, the caregiver may specify a desired VTBI or a desired duration. If the caregiver specifies a VTBI, then the infusion rate and duration may be automatically calculated based on the selected concentration, dose per unit, and VTBI. If the caregiver specifies an infusion duration, then the VTBI and infusion rate may be automatically calculated based on the selected concentration, dose per unit and infusion duration. FIG. 13 depicts an example user interface where the caregiver has selected to specify a VTBI. This interface likewise includes input elements (e.g., a keypad and slider) at which the caregiver may specify the desired value for the VTBI. Similar input elements may be provided to specify a value for the infusion duration where the caregiver opts to specify the infusion duration rather than the VTBI. In some circumstances, the caregiver may skip certain configuration steps, e.g., where the delivery substance does not have a dose (e.g., saline).



FIG. 14 depicts an example user interface at which the caregiver selects the action the infusion device should perform upon completing the continuous infusion. This interface includes various actions available for selection including a KVO action, a continue rate action, and a stop action. The interface also includes input elements at which the caregiver may specify a KVO rate or a continue rate. This interface further includes input elements at which the caregiver may configure an alarm when the continuous infusion nears completion. The interface includes input elements at which the caregiver may toggle the alarm on and off and specify how soon the alarm should be provided prior to completing the continuous infusion. In addition, this interface includes an input element at which the caregiver may specify a threshold for an air-in-line alarm. Having configured the parameters of the continuous infusion, the caregiver may start the infusion by selecting a “START” button at the interface. The caregiver may also select to start the infusion after a specified delay by selecting a “DELAYED START” button at the interface.


Once the primary infusion has started, the infusion device may display the parameters of the current infusion. FIG. 15 depicts an example user interface that displays the parameters of the primary infusion currently being delivered by the infusion device. As seen in FIG. 15, the parameters displayed include the substance being delivered, the dose, the rate, and the VTBI. The infusion device may update the interface as the VTBI changes throughout the infusion (e.g., from 100 mL remaining to 97 mL remaining). The interface may also include the remaining duration of the current infusion.


During the primary infusion, the caregiver may select and program a secondary infusion to be delivered along with the primary infusion. As seen in FIG. 15, the caregiver may select a secondary infusion type for the secondary line, e.g., a concurrent infusion or a piggyback infusion. The caregiver may navigate through user interfaces similar to those depicted in FIGS. 9-13 to specify the substance, concentration, dose per unit and corresponding value, and VTBI or duration value. Having configured the parameters of the secondary infusion, the caregiver may similarly specify an action to perform upon completion of the secondary infusion. FIG. 16 depicts an example user interface at which the caregiver may specify the action to perform upon completion of a piggyback infusion. As seen in FIG. 16, the actions available for selection include resuming infusion at the primary line, a KVO action at the secondary line, and stopping infusion at the secondary line. As also seen in FIG. 16, this interface includes a button to backprime the primary line before starting infusion at the secondary line. The caregiver may then select a button at the interface to start the secondary infusion with or without delay.


Once the secondary infusion has started, the infusion device may display the parameters of the current infusions. FIG. 17 depicts an example user interface that displays the parameters of both the primary and secondary infusions currently being delivered by the infusion device. This interface likewise displays the substances being delivered by the primary and secondary lines, as well as the respective concentrations, does, rates, and VTBI values.


In accordance with the screenshots above, FIGS. 18A-24 depict flowcharts for creating and configuring a continuous infusion procedure.



FIGS. 18A-18B depict a flowchart of example method steps for selecting a medication. As seen in FIGS. 18A-18B, the infusion device may be configured to display the infusion substances available for selection and initiate safety checks to determine whether the selected substance has already been selected for infusion at the current infusion device or another infusion device associated with the patient (i.e., a duplicate check) or if the selected substance is compatible with other substances selected for infusion (i.e., a compatibility check) at the current infusion device or other infusion devices associated with the patient. The infusion device may notify the caregiver of any potential duplicability or compatibility issues, which the caregiver may acknowledge and override if desired. As also seen in FIGS. 18A-18B, the caregiver may also select or specify, e.g., the desired concentration, VTBI, or indicators.



FIGS. 19A-19B depict a flowchart of example method steps for performing a safety check for duplicate infusion substances. As seen in FIGS. 19A-19B, the duplicate safety check may be performed with respect to multiple infusion devices associated with a patient (i.e., infusion device no. 1, infusion device no. 2, . . . , infusion device no. n). As described in further detail below, the infusion devices associated with the patient may be in signal communication with each other. In some implementations, the infusion devices may be set up in a master/slave configuration. As also seen in FIGS. 19A-19B, the infusion devices associated with a patient may also be in signal communication with a medication management system having medication safety software. Suitable medication safety software for the medication management system may include the Hospira MedNet™ Safety Software available from Hospira.


During the duplicate substance safety check, the infusion device may determine whether the selected substance has been selected for delivery on another line of the infusion device or during another step of the infusion sequence. The infusion device may also query the medication management system to determine whether the selected substance has been selected for delivery via another infusion device associated with the patient. Similarly, the infusion device may query the other infusion devices associated with the patient for a list of substances selected for delivery via those infusion devices. In response to the query, the other infusion devices may return a list of substances selected for delivery to the patient. The infusion device may then compare the selected substance to the respective lists of substances received from the other infusion devices. The infusion device may query other infusion devices it is connected to as a master or slave infusion device. The infusion device may also poll any nearby infusion devices and provide a unique identifier associated with the patient. If the polled infusion device indicates it is associated with the same patient (i.e., the patient identifiers match), then the infusion device may query from the polled computing device the list of substances selected for delivery via the polled computing device. If the infusion device determines that the selected substance matches a substance selected for delivery via another infusion device, then the infusion device may provide a notification or warning to the caregiver.



FIGS. 20A-20B depict a flowchart of example method steps for performing a safety check for compatible infusion substances. The compatibility safety check may be similar to the duplicate safety check discussed above. In particular, the compatibility safety check may likewise involve querying and polling multiple infusion devices associated with a patient and querying a medication management system to determine whether the selected substance is compatible with the selected substance. If the infusion device determines that the selected substance is (or is potentially) incompatible a substance selected to be delivered via another infusion device associated with the patient, then the infusion device may provide a notification or warning to the caregiver.



FIGS. 21A-21B depict a flowchart of example method steps for specifying a dose for the selected substance at the infusion device. As seen in FIGS. 21A-21B, the caregiver may select from a list of available dosing units for the selected substance displayed by the infusion device and specify a desired dose. The infusion device may include or be in signal communication with a library that specifies a default dose for the selected substance. The infusion device may allow the caregiver to specify a body surface area (BSA) dose (e.g., kilograms/kg or square meters/m2) or a patient weight-based dose. For a BSA dose, the infusion device may allow the caregiver to specify the patient weight and height and automatically calculate the patient BSA. The caregiver may also specify the rate of infusion, or the infusion device may be configured to calculate the rate (e.g., mL/hour) based on the concentration, dose, and weight or BSA.



FIG. 22 depicts a flowchart of example method steps for specifying a VTBI. As seen in FIG. 22, the infusion device may allow the user to specify the desired VTBI value and calculate an infusion duration based on that value.



FIG. 23 depicts a flowchart of example method steps for confirming an infusion configured at the infusion device. As seen in FIG. 23, the infusion device displays the parameters selected for the infusion so that the caregiver may review them. The infusion device may also be configured to wait a user-selectable number of seconds before allowing the caregiver to confirm the parameters to ensure the caregiver has had enough time to review them. If the infusion involves multiple steps, the caregiver may advance to the next step in the infusion sequence to review the parameters configured for that step. If the infusion is an intermittent infusion, the infusion device may be configured to request confirmation of the parameters of only one of the intermittent infusion as well as the total number of intermittent infusions and the time between steps. Once all steps have been reviewed, the caregiver may start the infusion or initiate a delayed start for the infusion. At the infusion start time, the infusion device may begin the infusion sequence.


The infusion device described herein is also configured to allow a caregiver to add a step to a current ongoing continuous infusion thus converting the current continuous infusion into one of the advanced infusion types. In other words, the caregiver may convert a current continuous infusion into one of an intermittent, multi-step, inter-channel sequencing, or “infinite” flow infusion. The infusion device leverages the recognition that the advanced infusion types may be viewed as a series of continuous infusions delivered in sequence. In particular, an intermittent infusion may be recognized as a series of identical continuous infusions separated by a delay. A multi-step infusion may be recognized as a series of continuous infusions using the same substance at the same concentration and indication, but differing in dose, rate, or both dose and rate. An inter-channel sequencing infusion may be recognized as a series of continuous infusions delivered from different lines via different channels. An “infinite” flow infusion may be recognized as a series of continuous infusions delivered from different lines on the same channel.



FIG. 24 depicts a flowchart of example method steps for converting a current continuous infusion to one of the various advanced infusion types. As seen in FIG. 24, the caregiver may select a substance for infusion and, if the selected substance permits multiple infusion steps to be performed, the caregiver may choose to add a step to the current infusion. For the additional step, the caregiver may select or specify a dose and VTBI as described above. If the desired infusion type is an “infinite” flow infusion (i.e., there is only one step in the infusion sequence), then the caregiver may specify the volume of the delivery source container and configure the parameters for the “infinite” flow infusion. If the desired infusion type is an intermittent infusion (i.e., there is one repeated step), then the caregiver may clone the current step and configure the parameters for the intermittent infusion.


After the caregiver has added a step to the current infusion, the caregiver may select to view all steps for the infusion sequence at the infusion device. The caregiver may select one of the steps to view in further detail at the infusion device or to delete from the infusion sequence. Once the caregiver has configured all the desired steps for the infusion sequence, the caregiver may confirm the infusion steps and the infusion sequence as described above.



FIG. 25 depicts an example user interface of an infusion device at which the caregiver may add a step to an infusion sequence at the infusion device. As seen in FIG. 25, a caregiver may select a substance to be delivered to the patient and the corresponding delivery parameters as discussed above. The user interface also includes a button to add a step to the current infusion sequence as well as a button to clone the current step of the infusion sequence. The user interface may be configured to display in a pop-up menu additional buttons that allow the caregiver to specify whether the new step should be added to the infusion sequence either before or after the current step. The user interface may be configured to display the pop-up menu after a long press (i.e., n number of seconds) on the button to add a new step. The user interface in FIG. 25 also includes a “Mode” button that allows the caregiver to convert or configure the continuous infusion as an advanced infusion type (e.g., TPN, intermittent, multi-step, inter-channel sequencing, or “infinite” flow).



FIGS. 26A-26B depict a flowchart of example method steps for adding a new step to a current infusion sequence at an infusion device. As seen in FIGS. 26A-26B, the caregiver may select to add a step to the current infusion at the infusion device and specify whether the new step should be before or after the current step of the infusion. The infusion device may be configured to pre-populate the new step with the substance selected for the current step. If the caregiver specifies a new concentration for the new step, the infusion device may automatically calculate the VTBI based on the new concentration.


If the new step is added for an inter-channel sequencing infusion, the caregiver may select to change the infusion line for the new step, as well as add new infusion devices for the inter-channel sequencing infusion. If the caregiver selects to add a new infusion device, then the infusion device may display a list of infusion devices available to add, and the caregiver may select one of the infusion devices listed. If the caregiver has selected to change the line for the infusion during an inter-channel sequencing infusion, the infusion device may clear the substance selected for the current step allowing the caregiver to select a new substance to be delivered during the new step of the inter-channel sequencing infusion. The caregiver may also specify whether the new step for the inter-channel sequencing infusion should be performed concurrently with another step in the sequence.



FIG. 27 depicts an example user interface of an infusion device for changing the line for an inter-channel sequencing infusion. As seen in FIG. 27, the interface displays the currently selected infuser, line, and channel. The interface also displays a list of lines available at the infusion device that may be selected for the infusion step currently being configured at the infusion device. In this example, the infusion device includes two channels (e.g., a Left Channel and a Right Channel) and two lines per channel (e.g., Line A and Line B for the Left Channel and Line C and Line D for the Right Channel). As also seen in FIG. 27, the list of lines may also identify one or more infusion devices in signal communication with the current infusion device with lines available to be selected for the current infusion step.


Selecting additional infusion devices to perform a step of an infusion sequence may be referred to as “ganging” the infusion devices together for coordinated operation of an infusion to a patient. In addition, infusion devices that have each been configured to perform at least one step in an infusion sequence may be referred to as “ganged” infusion devices. FIG. 28 depicts a flowchart of example method steps for ganging infusion devices. As seen in FIG. 28, a caregiver may gang infusion devices together via a medication management system that interconnects multiple computing devices such that they are in signal communication with each other. As also seen in FIG. 28, a caregiver may gang infusion devices together by setting up a master/slave configuration between the computing devices without a medication management system. For this alternative approach to ganging infusion devices together, an infusion device may perform a device discovery operation to locate any nearby infusion devices or any other infusion devices associated with the current patient. As described in further detail below, infusion devices may be in signal communication with each other via wired, wireless, or both wired and wireless communications.


For multi-step infusion sequences, the infusion device may allow the caregiver to view a list of the steps configured for an infusion sequence. FIG. 29 depicts a flowchart of example method steps for viewing and manipulating the list of infusion steps configured for an infusion sequence. As seen in FIG. 29, the caregiver may select to view the list of infusion steps, and the infusion device may display the list with the steps in their current order. The user may select one of the steps (e.g., by tapping the step), and the infusion device may display details for the selected step. The caregiver may also drag the selected step (e.g., by pressing and holding the step), to move or delete the selected step (e.g., drag and release). The caregiver may drag the step up or down to reposition the step in the list of steps (e.g., drag step no. 3 down to become step no. 5 and drag step. no 4 up. to become step no. 2). The caregiver may also drag the step right or left to delete the step from the list. The infusion device may be configured with an undo function that allows the caregiver to display a list of removed steps and select a removed step to add back to the list.



FIGS. 30-33 depict example user interfaces of an infusion device for displaying and manipulating a list of infusion sequence steps. FIG. 30 depicts an example user interface displaying a list of infusion sequence steps for an infusion to be delivered by an infusion device. As seen in FIG. 30, the list of infusion steps identifies, for each step, the infusion device, the line, the substance, and the infusion parameters associated with the step (e.g., substance, concentration, dose, rate, VTBI, and time). FIG. 31 depicts an example user interface of an infusion device for displaying the parameters associated with a step the caregiver has selected in the list of infusion steps. Similar to each step displayed in the list, the interface displays the details of the selected step (e.g., substance, concentration, dose, rate, VTBI, and time). FIG. 32 depicts the user interface of FIG. 30 in which the caregiver has selected one of the steps (step no. 4) in the list of infusion steps. FIG. 33 depicts the user interface of FIG. 32 in which the caregiver has dragged the selected step to the right to remove it from the list. As noted above, the user interface in FIG. 33 may also display a button to undo the removal of the removed step.


As noted above, a caregiver may convert a continuous infusion to an intermittent infusion. The continuous infusion being converted may be currently ongoing at the infusion device, i.e., the infusion device may currently be delivering a substance to the patient. The continuous infusion being converted may also be an infusion that has been configured but not yet started at the infusion device. The ability to convert a continuous infusion to an intermittent infusion may depend on the substance being infused. Some substances may permit intermittent infusion while other substances may not. Accordingly the infusion device may query a library of substances (e.g., a drug library) to determine whether intermittent infusion of the current substance is permitted. In addition, the infusion device may not permit a caregiver to convert a continuous infusion to an intermittent infusion until the continuous infusion has been fully configured.



FIG. 34 depicts a flowchart of example method steps for converting a continuous infusion to an intermittent infusion. After a continuous infusion has been configured, the caregiver may select a button at a user interface of the infusion device to display the options for an intermittent infusion. The caregiver may then select or specify the number of infusion steps for the intermittent infusion. The infusion device may limit the total number of infusion steps for the intermittent infusion based on a permitted range for the selected substance. The infusion device may likewise query a substance library (e.g., a drug library) for the permitted range. The caregiver may also select or specify the time delay between each step of the intermittent infusion as well as callback options for the intermittent infusion. A callback refers to a notification provided to the caregiver at the end of an individual infusion step as well as at the end of the intermittent infusion.



FIG. 35 depicts a flowchart of example method steps for specifying one or more callback options. The infusion device may display a list of callback options available for selection, and the caregiver may select a callback option to be provided upon completion of one or more individual infusion steps or upon completion of the entire intermittent infusion. The caregiver may also specify that the infusion device should not provide a callback for one or more of the individual infusion steps or the intermittent infusion.



FIG. 36 depicts an example user interface for cloning a current step of an intermittent infusion. As seen in FIG. 36, the user interface display the current line of the infusion device and the allowable range for the total number of infusion steps that may be performed for the substance in an intermittent infusion. The user interface includes a keypad at which the caregiver may specify the total number of infusion steps (i.e., deliveries) that should be performed. The user interface may also allow the caregiver to specify the delay between steps, and options for each step (e.g., callback options).



FIG. 37 depicts a flowchart of example methods steps for configuring an intermittent infusion. As seen in FIG. 37, the caregiver may select a substance to be delivered to the patient, the intermittent infusion options, the dose, and the VTBI. With the intermittent infusion configured, the caregiver may confirm the parameters.


As also noted above, a caregiver may also convert a continuous infusion at the infusion device to an “infinite” flow infusion. As noted above, an “infinite” flow infusion refers to an infusion in which an infusion device utilizes two delivery lines on a single cassette channel wherein the infusion device automatically switches to the other line when the current line completes its infusion such that there is no interruption in the delivery. Each delivery line may be connected to a respective delivery source such that the caregiver may replace a depleted delivery source with a full delivery source while the other delivery source continues to deliver the substance to the patient. The switching between delivery sources allows the caregiver to continually swap out depleted delivery sources during the infusion without interrupting the continuous delivery of the substance to the patient. In this way, the infusion may continue while new delivery sources are connected to the infusion device. Infusion may thus continue without pausing to connect new containers.



FIG. 38 depicts a flowchart of example method steps for converting a continuous infusion to an “infinite” flow infusion and configuring the “infinite” flow infusion. After a continuous infusion has been configured, the caregiver may select a button at a user interface of the infusion device to display the options for an “infinite” flow infusion. Like converting to an intermittent infusion, the ability to convert a continuous infusion to an “infinite” flow infusion may be restricted until the continuous flow infusion has been fully configured.


When the caregiver selects to convert and configure an “infinite” flow infusion, the infusion device may display options for the “infinite” flow infusion. As seen in FIG. 38, the caregiver may, if necessary, specify at the infusion device a KVO rate. With the total VTBI having already been configured, the infusion device requests that the caregiver specify the volume of the delivery sources that will be used for the “infinite” flow infusion. The infusion device also requests that the caregiver indicate whether the additional and subsequent delivery sources with be attached to the infusion device before or after the delivery sources are fully depleted. If the caregiver indicates the delivery sources will be replaced before they are fully depleted, the caregiver may configure a callback such that the caregiver is notified a predetermined amount of time before the delivery source is fully depleted (e.g., x number of minutes or seconds). If the caregiver indicates that depleted delivery sources will be replaced after they are depleted, the infusion device may prompt the caregiver to attach one or more additional delivery sources to the infusion device before the “infinite” flow infusion begins.



FIG. 39 depicts a flowchart of example method steps for configuring an “infinite” flow infusion. As seen in FIG. 39, the caregiver may select the substance to be delivered to the patient, the dose, and the volume of the delivery sources that will be used for the “infinite” flow infusion. Once the volume of the delivery sources has been specified, the caregiver may specify the total VTBI of the total infusion duration. If the caregiver specifies the VTBI, then the infusion device may automatically calculate the total infusion duration. If the caregiver specifies the total infusion duration, then the infusion device may automatically calculate the VTBI. The caregiver may then specify various options for the “infinite” flow infusion such as the KVO rate and the callback options as discussed above. As also noted above, the infusion device will prompt the caregiver to connect an addition delivery source to the infusion device prior to starting the infusion if the caregiver opts to be notified when a delivery source is depleted. The caregiver may then connect a new delivery source to the infusion device after each delivery source that empties. As also noted above, the caregiver may opt to be notified prior to the depletion of a delivery source in which case the caregiver may only connect the subsequent delivery source when the current delivery source is near empty. Waiting to connect a subsequent delivery source until receipt of notification may be advantageous where the substances delivered to the patient are in limited supply or need to be refrigerated. In other words, requesting notification of a near-empty delivery source allows the caregiver to connect the next delivery source only when it becomes necessary. Having configured the options for the “infinite” flow infusion, the caregiver may confirm and initiate the infusion at the infusion device.



FIGS. 40A-40B depict a flowchart of example method steps for an “infinite” flow infusion. As seen in FIGS. 40A-40B, the infusion device may request confirmation from the caregiver that the subsequent delivery source has been connected to the infusion device. When the caregiver connects the subsequent delivery source, the caregiver may confirm at the infusion device that the subsequent delivery source has been connected. The infusion device may also provide a notification to the caregiver that the current delivery source is near-empty as described above. The caregiver may respond to the notification by replacing the near-empty delivery source with a new delivery source. When the current delivery source has been depleted, the infusion device stops infusing on the current line, switches to the next line connected to a full delivery source, and begins infusing on the new line. If the infusion device has reached the VTBI or the total infusion duration, the infusion device may stop the infusion procedure or execute any end-of-procedure actions (e.g., infusing at a specified KVO rate). The infusion device may likewise notify the caregiver that the infusion procedure is complete.



FIG. 41A-B depict example user interfaces of an infusion device during an “infinite” infusion flow. As seen in FIG. 41A, the infusion device is currently infusing the patient via a first line (e.g., Line A) of the infusion device. When the delivery source connected to the first line is depleted, the infusion device switches to infuse the patient via another line of the infusion device. As seen in FIG. 41B, the infusion device has switched to infuse the patient via a second line (e.g., Line B) of the infusion device. A caregiver may thus replace the delivery source connected to the first line with a new delivery source to subsequently use when the delivery source for the second line is depleted.


As noted above, a caregiver may configure various secondary infusions (e.g., concurrent infusions and piggyback infusions) during an infusion currently being performed at the infusion device. FIGS. 42A-42B depict a flowchart of example method steps for selecting a secondary infusion at infusion device. As seen in FIGS. 42A-42B, the infusion device may display a user interface with buttons allowing the caregiver to select a secondary infusion via a selected line at the infusion device. The caregiver may select a secondary infusion type (e.g., concurrent or piggyback) and the infusion device may determine whether the other line is currently infusing.


If the other line of the infusion device is currently infusing, then the caregiver may proceed with configuring the concurrent or piggyback infusion as described above. If, however, the other line of the infusion device is not currently infusing, then the infusion device may assess the status of the other line in order to provide notifications or warnings to the caregiver. As an example, the infusion device may notify or warn the caregiver that the other line is currently in a potential non-delivery condition exists, i.e., that the infusion device might not be able to perform the secondary infusion selected. A non-delivery condition may exist where the other line is delayed, is in standby, or has completed its infusion. If a non-delivery condition exists, the infusion device may notify the caregiver that the other line must be currently infusing in order to perform the secondary infusion via the selected line. The notifications and warnings may advantageously avoid situations where, e.g., the infusion device attempts to switch back to a line that may not resume an infusion upon completion of a piggyback infusion. The infusion device may prompt the caregiver to initiate or restart an infusion at the other line. Once initiated or restarted, the caregiver may proceed with configuring the parameters of the secondary infusion.



FIG. 61 depicts an example user interface of an infusion device for notifying or warning a caregiver regarding a non-delivery condition. As seen in FIG. 61, the user interface informs the caregiver that the infusion device cannot initiate a secondary infusion unless the other line is currently infusing. The user interface also includes buttons to cancel the secondary infusion or view the settings configured for the other line.



FIG. 62 depicts a flowchart of example method steps for configuring a piggyback infusion at an infusion device. As seen in FIG. 62, the caregiver may select or specify the substance to be delivered to the patient, the dose, the VTBI, and various piggyback infusion options (e.g., an action to perform at the end of the infusion). Once the parameters for the piggyback infusion have been configured, the caregiver may review the parameters and initiate the piggyback infusion. FIG. 63 depicts a flowchart of example method steps for configuring piggyback infusion options including selecting or specifying an action to perform at the end of the piggyback infusion.



FIG. 64 depicts a flowchart of example method steps for configuring a concurrent infusion. Like a piggyback infusion, the caregiver may select or specify the substance to be delivered to the patient, the dose, the VTBI, and various concurrent infusion options.


As also noted above, a caregiver may configure various advanced infusion types at an infusion device (e.g., TPN, intermittent, multi-step, inter-channel sequencing, and “infinite” flow). As also noted above, a caregiver may select an advanced infusion type via “Mode” button on the user interface to add a step to a continuous infusion. Alternatively, the infusion device may present a user interface with “quick mode” selection buttons.



FIG. 43 depicts an example user interface of an infusion device at which a caregiver may select to configure an advanced infusion type. The user interface includes buttons for configuring infusions at two infusion devices each having two lines. As seen in FIG. 43, the primary line (Line A) of the first infusion device is currently performing an infusion at the patient. The user may select to program another infusion at the secondary line (Line B) of the first infusion device such as a concurrent or piggyback infusion as discussed above. The caregiver may also select to configure an infusion at the primary line (Line C) or the secondary line (Line D) of the second infusion device. As also seen in FIG. 43, the caregiver may select one of the buttons to program a continuous infusion at the lines of the second infusion device or an advanced infusion type.



FIG. 44 depicts a flowchart of example method steps for selecting an advanced infusion type to configure at an infusion device. Upon selection of an advanced infusion type button, the infusion device may display a list of the advanced infusion types available for selection. As noted above, advanced infusion types may include TPN, intermittent, multi-step, inter-channel sequencing, and “infinite” flow. The user may then select the desired advanced infusion type and configure the parameters for the advanced infusion type selected.



FIG. 45 depicts a flowchart of example method steps for configuring a TPN infusion at an infusion device. As seen in FIG. 45, the caregiver may select a desired TPN protocol at the infusion device. Similar to the duplicate safety check for the substances delivered the patient, the infusion device may perform a duplicate safety check for the protocol selected. In particular, the infusion device may compare the selected TPN protocol to other TPN protocols that have been configured for the patient at the current infusion device or at other infusion devices associated with the patient. The safety checks may also include duplicate and compatibility safety checks for the substances delivered to the patient during the respective TPN protocols. In addition, if not already specified via the selected TPN protocol, the caregiver may select or specify a VTBI, total infusion duration, taper up time, taper down time, delivery source volume, and KVO rate for the selected TPN protocol. These parameters may be pre-populated based on the TPN protocol specified. The caregiver may also modify the pre-populated parameters at the infusion device. Once the selected protocol has been configured, the caregiver may confirm the selected parameters and initiate the TPN infusion.



FIG. 46 depicts a flowchart of example method steps for selecting a TPN protocol at an infusion device. As seen in FIG. 46, the infusion device displays the TPN protocols available for selection, and the caregiver may select one of the TPN protocols displayed. The infusion device may then determine whether the selected protocol has already been configured at the current infusion device or another infusion device associated with the patient. If so, the infusion device may display a notification to the caregiver indicating that the selected TPN protocol is (or may be) a duplicate TPN protocol currently being delivered or scheduled for delivery to the patient. The caregiver may acknowledge the notification indicating the potentially duplicate TPN protocol. The infusion device may also determine whether the selected TPN protocol is compatible with substances currently being delivered or scheduled to be delivered to the patient. The infusion device may notify or warn the caregiver when it determines that the TPN protocol is (or may be) incompatible with the substances considered. The caregiver may likewise acknowledge the notification or warning and respond accordingly. The caregiver may, for example, select to override the potential incompatibility and continue with the selected TPN protocol.



FIG. 47 depicts a flowchart of example method steps for configuring a multi-step infusion at an infusion device. As seen in FIG. 47, the caregiver may select the substance to be delivered to the patient as well as the total number of infusion steps to perform. For each infusion step, the caregiver may specify the dose and VTBI for the infusion step. Once the caregiver has configured the parameters for all of the infusion steps for the multi-step infusion, the caregiver may confirm and initiate the multi-step infusion.



FIGS. 48-55 depict example user interfaces and flowcharts of example method steps for configuring an inter-channel sequencing infusion. FIG. 48 depicts a flowchart of example method steps for configuring an inter-channel sequencing infusion. As seen in FIG. 48, caregiver may configure an inter-channel sequencing infusion by selecting a pre-defined protocol from a library of protocols or manually configure each infusion step of the inter-channel sequencing infusion. As also seen in FIG. 48, the infusion device may request confirmation from the caregiver of each step in the inter-channel sequencing infusion. During confirmation of each infusion step, the infusion device may also prompt the caregiver to set up the delivery source for the infusion step being confirmed.



FIG. 49 depicts a flowchart of example method steps for selecting a pre-defined inter-channel sequencing protocol. As seen in FIG. 49, the caregiver may select an inter-channel sequencing protocol to deliver to the patient. The caregiver may also gang multiple infusion devices together to deliver the inter-channel sequencing infusion. The caregiver may assign one or more of the infusion steps of the selected protocol to individual infusion devices ganged together. Once the infusion steps for the inter-channel sequencing protocol have been configured and assigned to respective infusion devices, the caregiver may confirm and initiate the inter-channel sequencing infusion.



FIG. 50 depicts an example user interface for selecting an inter-channel sequencing protocol at an infusion device. As seen in FIG. 50, the infusion device may display a list of inter-channel sequencing protocols available for selection. The caregiver may select one of the protocols from the list, and the user interface may subsequently display an interface for selecting the ganged together infusion devices to perform the selected protocol and an interface for confirming the parameters configured for the selected protocol.


Like the other advanced infusion types, the infusion device may perform safety checks based on the selected inter-channel sequencing protocol. FIG. 51 depicts a flowchart of example method steps for performing safety checks based on a selected inter-channel sequencing protocol. Like the safety checks discussed above, the safety checks may include a duplicate safety check and a compatibility safety check to check whether any duplicate or incompatible substances are being delivered or are scheduled to be delivered to the patient during the inter-channel sequencing infusion. The infusion device may similarly notify or warn the caregiver if the infusion device identifies any duplicate or incompatible substances. The caregiver may also likewise acknowledge and override the notification or warning.


As noted above, inter-channel sequencing infusion may involve multiple infusion devices. An infusion device may allow a caregiver to identify and gang together additional infusion devices to be utilized during an inter-channel sequencing infusion. The process of ganging infusion devices together will be discussed in further detail below.



FIG. 52, however, depicts an example user interface of an infusion device for listing and selecting infusion devices to be used in an inter-channel sequencing infusion. As seen in FIG. 52, the user interface displays a list of infusion devices in signal communication with the current infusion device that may be ganged together for the inter-channel sequencing infusion. The list of infusion devices may include a unique identifier for the available infusion devices and the total number of lines available at each of the infusion devices. The caregiver may select one or more of the available infusion devices from the list to include in the inter-channel sequencing infusion currently being configured at the infusion device. As also seen in FIG. 52, the user interface includes a button to poll infusion devices (e.g., wirelessly) that are nearby the current infusion device. Polling nearby infusion devices will be discussed in further detail below. Upon selection of one of the available infusion devices, a notification may be transmitted to the selected infusion device that the caregiver has selected it to be ganged to the current infusion device. Upon receipt of the notification, the selected infusion device may display a confirmation request. FIG. 53 depicts an example user interface of an infusion device displaying a confirmation request to gang the infusion device to another infusion device. As seen in FIG. 53, the confirmation request includes the respective identifiers for the infusion devices and buttons allowing the caregiver to confirm or deny the request. The user interface in FIG. 52 also depicts how the list of available infusion devices is updated upon the confirmation or denial of a request to gang a selected infusion device to the current infusion device.


For an inter-channel sequencing infusion, one of the infusion devices may be designated the master infusion device and the other infusion devices may be designated the slave infusion devices. The infusion device at which the caregiver configures the inter-channel sequencing infusion and adds additional infusion devices to the inter-channel sequencing infusion may be designated as the master infusion device for the infusion. The additional infusion devices added to the inter-channel sequencing infusion may be designated as the slave infusion devices. The notification sent to a selected infusion device from the master infusion device may be sent via a medication management system the infusion devices are connected to. Additionally or alternatively, the notification sent to a selected infusion device from the master infusion device may be sent via a direct wired or wireless communication between the master infusion device and the slave infusion device. Similarly, the response to the confirmation request (e.g., confirmed or denied) may be sent back to the master infusion device from the selected infusion device via a medication management system or via a direct wired or wireless communication between the infusion devices.


The master infusion device may also be configured to confirm that the number of infusion devices needed to carry out the inter-channel sequencing infusion have been ganged together. As one example, the total number of infusion lines may be required to match the total number of unique substances selected to be delivered to the patient, and the master infusion device may be configured to confirm that enough infusion devices have been ganged together to provide the total number of infusion lines needed. If the caregiver attempts to proceed to the review screen without having selected the number of infusion devices needed to carry-out the inter-channel sequencing infusion, the infusion device may display a notification that additional infusion devices are needed. In some example implementations, a “review” button may be inactive until the caregiver has selected enough infusion devices.


Once the caregiver has selected enough infusion devices for the inter-channel sequencing infusion, the infusion device may prompt the caregiver to respectively assign an infusion line to each step in the infusion. FIG. 54 depicts a user interface of an infusion device for assigning infusion lines to steps of an inter-channel sequencing infusion. As seen in FIG. 54, the user interface displays the details of the currently selected step of the inter-channel sequencing infusion including, e.g., the substance to be delivered, the dose, and the VTBI. The user interface also displays a list of the infusion devices that have been ganged together for the inter-channel sequencing infusion. The caregiver may select one of the infusion devices, and the user interface may display the lines of the selected infusion device that are available to be assigned to the current step. The caregiver may proceed through the steps of the inter-channel sequencing infusion and select a line to be assigned to each respective step. The user interface may deactivate (e.g., gray out) or hide selections for lines of infusion devices that have already been assigned to an infusion step. The user interface may also deactivate or hide selections of infusion devices that have no lines remaining to be assigned to an infusion step. In some implementations, the infusion device may allow the caregiver to associate an infusion device and line when an infusion device is selected for the inter-channel sequencing infusion.


As noted above, the caregiver may specify the parameters for each step in an inter-channel sequencing infusion as the infusion steps are added to the sequence. FIG. 55 depicts a flowchart of example method steps for configuring the steps of an inter-channel sequencing infusion. As seen in FIG. 55, the caregiver may select or specify, for each step, a dose, VTBI, and delay offset. Once the step is fully specified, the caregiver may proceed to the next step in order to specify the parameters for that step. The delay offset may be an optional parameter. Once all steps are configured, the caregiver may review the steps of the inter-channel sequencing infusion and initiate the infusion at the infusion device. During the review and confirmation process, the infusion device may remind the caregiver to ensure the delivery sources have been setup and connected to the infusion devices.


During the inter-channel sequencing infusion, the infusion devices may provide a visual indication to indicate their status as either the master infusion device or one of the slave infusion devices. FIG. 56A-B depict respective user interfaces that include a visual indicator to identify the infusion device as a master or slave infusion device. As seen in FIG. 56A, the user interface of the infusion device includes a dark-colored background (e.g., dark blue) to identify the infusion device as the master infusion device. As seen in FIG. 56B, the user interface of the infusion device includes a light-colored background (e.g., light green) to identify the infusion device as a slave infusion device. Additional and alternative types of visual indicators may be selectively employed to visually distinguish master and slave infusion devices.



FIG. 57 depicts an example of a possible inter-channel sequencing infusion that may be implemented utilizing the infusion devices described herein. As seen in FIG. 57, three infusion devices are connected to a patient: a first dual LVP infusion device connected to three delivery sources (A, B, and, C); a second syringe infusion device connected to one delivery source (D); and a third single LVP infusion device connected to two delivery sources (E and F). As also seen in FIG. 57, the dual LVP infusion device has been designated the master infusion device while the syringe infusion device and the single LVP infusion device have been designated slave infusion devices. The master infusion device in FIG. 57 is in signal communication with the slave communication devices via wireless communications. An example inter-channel sequencing infusion performed by the infusion devices in FIG. 57 may be, for example: flush from delivery source A; infuse from delivery source B; flush from delivery source A; infuse from delivery sources C and D together; flush from delivery source A; deliver from delivery source E; flush from delivery source A; deliver from delivery source F; and flush from delivery source A. In some example implementations, the each of the delivery sources may be connected to a manifold (e.g., an omni-flow manifold), and the manifold may be connected to an infusion device to infuse the patient from all of the delivery sources via a single channel.


As noted above, a caregiver may also manually configure an inter-channel sequencing infusion rather than select from a list of predefined protocols. FIG. 58 depicts a flowchart of example method steps for configuring the steps of an inter-channel sequencing infusion manually. As seen in FIG. 58, the caregiver may select one or more infusion devices to utilize for the inter-channel sequencing infusion. The caregiver may select the infusion devices to use as described above. Having selected the infusion devices, the caregiver may specify the total number of steps to be performed for the inter-channel sequencing infusion. The caregiver may configure an infusion step to include one or more deliveries to the patient. For each step, and for each delivery in a step, the caregiver may assign an infusion device and line to the current step and the current delivery of that step. The caregiver may also select or specify, for the current delivery of the current step, the substance to be delivered to the patient, the dose, and the VTBI. The caregiver may also specify a delay offset. The caregiver may repeat these actions for each delivery of the current step. Once all deliveries of the current step have been configured, the caregiver may proceed to the next step in the infusion sequence and likewise configure each delivery for the next infusion step selected. The caregiver may also view at the infusion device all steps of the inter-channel sequencing infusion, review the steps, and initiate the infusion.



FIGS. 59-60 depict example user interfaces of an infusion device for configuring the steps of an inter-channel sequencing infusion. FIG. 59 depicts a user interface for configuring the first delivery of the second step of an inter-channel sequencing infusion. As seen in FIG. 59, the user interface displays the selected infusion and line, the substance to be delivered to the patient and its concentration, the dose and units, the weight/BSA, the delivery rate, the VTBI, and the total delivery duration. The user interface in FIG. 59 also includes a button to specify whether or not the current delivery should be delivered concurrent with the other deliveries of the current step. The user interface in FIG. 59 additionally includes buttons to configure options for the current delivery of the current step (e.g., a delay offset), view all the steps of the infusion, confirm the parameters set for the current delivery of the current step, and advanced to the next delivery or step of the infusion. As described above, the multi-step view may allow that caregiver to select steps and deliveries, rearrange steps and deliveries, or delete steps and deliveries. The user interface in FIG. 60 includes similar information for the second delivery of the sixth step in the infusion sequence. As seen in FIG. 60, the user interface includes the unique identifier of the infusion device that has been assigned to the current step.


Interconnected Infusion Devices

As noted above, the infusion devices described herein may include communication modules that allow infusion devices to interconnect with one another for inter-channel and inter-device sequencing for infusion procedures. The communication modules may thus facilitate device-to-device communications as well as communications between infusion devices via a medication management system. Communications between infusion devices may be wired or wireless, via an MMS, or via an interconnecting device such as, e.g., a backplane, rack, or dock. Communication between infusion devices may also enable infusions between different types of infusion devices (e.g., LVP, syringe, and PCA infusion device types) as well as inter-channel sequencing programs in which multiple deliveries are infused within one step. Moreover communications between infusion devices may advantageously permit the use of pre-programmed inter-channel sequencing protocols for infusions to a patient.



FIG. 65, depicts an example of an implementation of an infusion device 6500 is shown. The infusion device 6500, in this example, includes a wireless network interface 6502 and a wired network interface 6504. The infusion device 6500 may be in signal communication with an interconnecting device 6506 via a communication port 6508 of the wired network interface 6504. The infusion device 6500 may also be in signal communication with one or more infusion devices 6510 via an antenna 6512 of a transceiver 6514 of the wireless network interface 6502. Through the interconnecting device 6506, the infusion device 6500 may be in signal communication with another infusion device 6516 as well as a medication management system 6518. The infusion device 6500 may also be in signal communication with the MMS 6518 via the wireless network interface 6502.


The interconnecting device 6506 may be, e.g., a wired backplane, dock, or rack that mounts or otherwise supports multiple infusion devices. The multiple infusion devices mounted at the interconnecting device may be housed in a common housing. The interconnecting device 6506 may be configured such that one of the infusion devices mounted at the interconnecting may be considered to be a lead infusion device. As an example, in an interconnecting device in which infusion devices are mounted from top-to-bottom, the lead infusion device may be the top-most infusion device. As another example, in an interconnecting device in which infusion devices are mounted from left-to-right, the lead infusion device may be the left-most infusion device. Additional examples will be appreciated with the benefit of this disclosure. The subsequent infusion devices may be subordinate to the lead infusion device based on their position at the interconnecting device in the sequence of infusion devices. For example, the next leading infusion device may be the infusion device just below the top-most infusion device or just to the right of the left-most infusion device and so forth.


The wireless network interface 6502 may be configured to exchange wireless communications with other infusion devices or an MMS using one or more wireless communication protocols. Example of suitable wireless communications protocols include radio-frequency identification (RFID) protocols, one or more of the IEEE 802.11 protocols (e.g., 802.11a, 802.11b, 802.11g, 802.11n), Bluetooth protocols, and other wireless communication protocols suitable for interconnecting infusion devices.



FIG. 66 depicts an example of a set of interconnected infusion devices 6600. As seen in FIG. 66, a first set of infusion devices 6602 are mounted at a first interconnecting device 6604, and a second set of infusion devices 6606 are mounted at a second interconnecting device 6608. As also seen in FIG. 66, one of the infusion devices 6610 at the interconnecting device 6604 has been designated the master infusion device. The other infusion devices 6612 at the interconnecting device 6604 have been designated slave infusion device. In addition, the master infusion device 6610 is in wireless signal communication with the interconnecting device 6608. When wireless communication with infusion devices of an interconnecting device, the infusion devices mounted at that interconnecting device may be considered as a singular unit. In FIG. 66, each of the infusion devices 6614 at the interconnecting device 6608 have been designated slave infusion devices. The master infusion device 6610 is also in direct wireless signal communication with an infusion device 6616 that has been designated a slave infusion device as well as an infusion device 6618 via an MMS 6620. The infusion device 6618 interconnected to the master infusion device 6610 via the MMS 6620 has also been designated a slave infusion devices.


As described in further detail below, interconnected infusion devices may designate a master infusion device when an MMS is and is not present. Designating a master infusion device via an MMS will be discussed in further detail below. If an MMS is not present, however, interconnected infusion devices may designate a master infusion device based on whether the infusion devices are in signal communication wirelessly or via an interconnecting device. If interconnected via an interconnecting device, the infusion devices may designate the lead infusion device as the master infusion device (e.g., the top-most or left-most infusion device). If communication with the master infusion device is lost, then the infusion devices may designate a new master infusion device which may be the next infusion device subordinate to the master infusion device in the sequence of infusion devices (e.g., the next top-most or next left-most infusion device). If the infusion devices are interconnected wirelessly, then the infusion devices may designate the infusing device having the longest infusion duration as the master infusion device. If communication with the master infusion device is lost, then the infusion devices may designate the infusion device having the next longest infusion duration as the new master infusion device. Designating the master infusion device when an MMS is not present will also be discussed in further detail below.



FIG. 67 depicts interconnected infusion devices respectively associated with patients. As seen in FIG. 67, a set of ganged together infusion devices 6702 are associated with a first patient (Patient A). The ganged infusion devices 6704 and 6706 of the set of infusion devices 6702 are in wireless signal communication with each other. One of the infusion devices 6704 has been designated the master infusion device, and two of the infusion devices 6706 have been designated as slave infusion devices. Another infusion device 6708 is associated with another patient (Patient B). As seen in FIG. 67, the master infusion device 6704 may be in the vicinity of the other infusion device 6708 and thus in signal communication with the other infusion device. As explained in further detail below, however, the other infusion device 6708 may not be available to be ganged with the set of ganged infusion devices 6702 since it is associated with a different patient (i.e., Patient B vs. Patient A).



FIG. 68 depicts a flowchart of example method steps for ganging together infusion devices via a medication management system. An infusion device connects to an MMS (block 6802). In response to connecting to the infusion device, the MMS updates a list of infusion devices (block 6804). The list of infusion devices maintained at the MMS may identify the patient each infusion device is respectively associated with (e.g., using a unique identifier respectively associated with each patient). The MMS may also query an infusion device to determine which patient the infusion device is associated with. A caregiver initiates the ganging procedure at one of the infusion devices connected to the MMS (block 6806). The infusion device at which the ganging process is initiated may be designated as the master infusion device.


The master infusion device then queries the MMS for a list of infusion devices available to be ganged to the master infusion device (block 6808). In response to the query, the MMS responds to the master infusion device with the list of available infusion devices (block 6810). The MMS may generate the list of available infusion devices based on the patient the master infusion device is associated with. The list of available infusion devices may, for example, only include infusion devices currently associated with the patient or, additionally or alternatively, infusion devices that have not yet been assigned to a patient and thus available to be associated with the patient the master infusion device is associated with. The master infusion device displays the list of available infusion devices (block 6812), e.g., at a display screen for review by the caregiver. The master infusion device receives from the caregiver a selection of one of the available infusion devices to gang to the master infusion device (block 6814). The master infusion device then transmits the selection to the MMS (block 6816), and the MMS in turn transmits a notification of the selection to the selected infusion device (block 6818).


In response to receipt of the notification, the selected infusion device displays (e.g., at a display screen) a confirmation request for the caregiver to confirm the selected infusion device should be ganged to the master infusion device as a slave infusion device (block 6820). If the caregiver does not confirm that the selected infusion device should be ganged to the master infusion device (block 6822: N), then the selected infusion device is not ganged to the master infusion device (block 6924). If, however, the caregiver does confirm that the selected infusion device should be ganged to the master infusion device (block 6822: Y), then the selected infusion device is ganged to the master infusion device (block 6826). The caregiver may gang multiple infusion devices to the master infusion devices. Accordingly, if the caregiver wishes to gang additional infusion devices to the master infusion device (block 6828: Y), the caregiver may repeat the steps above to gang additional infusion devices to the master infusion device. If the caregiver does not wish to gang additional infusion devices to the master infusion device (block 6828: N), or once the caregiver has ganged the desired number of infusion devices to the master infusion device, the caregiver may provide the infusion sequence configuration information to the master infusion device (block 6830). Once the caregiver has configured and confirmed the inter-device infusion sequence, the caregiver may initiate the infusion sequence and the master infusion device controls the infusion sequence across the ganged infusion devices (block 6832).



FIG. 69 depicts a flowchart of example method steps for ganging together infusion devices via direct communications. A caregiver initiates the ganging procedure at an infusion device configured to exchange direct communications (e.g., wired or wireless) with other infusion devices. (block 6902). The infusion device at which the ganging process is initiated may likewise be designated as the master infusion device. The master infusion device polls nearby infusion devices with a query message that may include a unique identifier (ID) for the patient associated with the master infusion device (block 6904). The patient ID may indicate the patient an infusion device is associated with, and in infusion device may store the patient ID. Nearby infusion devices may include infusion devices mounted at the same interconnecting device as the master infusion device as well as infusion devices within a broadcast range of the master infusion device. Accordingly the master infusion device may poll nearby infusion devices with a query message transmitted via a wired or wireless communication.


A polled infusion device may receive the query message from the master infusion device and compare the patient ID included in the query message with its stored patient ID (block 6906). If the patient IDs do not match (block 6908: N), then the polled infusion device may transmit a response to the master infusion device indicating that the patient IDs do not match (block 6910) and that the polled infusion device is thus unavailable to be ganged to the master infusion device. If, however, the patient IDs do match (block 6908: Y), then the polled infusion device may assess whether it is available to be ganged to the master infusion device. If the polled infusion device is not available to be ganged to the master infusion device (block 6912: N), then the polled infusion device may respond to the master infusion device that it is currently unavailable. Alternatively the polled infusion device may simply not respond to the master infusion device if it is currently unavailable. If, however, the polled infusion device is available (block 6912: Y), then the polled infusion device may respond to the master infusion device indicating that it is available to be ganged to the master infusion device (block 6916). The polled infusion device may also respond to the master infusion device indicating that is available to be ganged to the master infusion device if the polled infusion device is not currently associated with a patient.


Multiple infusion devices may respond to the master infusion device indicating they are available to be ganged to the master infusion device. Once the master infusion device has received response from the polled infusion devices, the master infusion device generates and displays a list of infusion devices that are available to be ganged together (block 6918). The master infusion device then receives from the caregiver a selection of one of the infusion devices to gang to the master infusion device (block 6920). The master infusion device then transmits a notification of the selection to the selected infusion device (block 6922).


In response to receipt of the notification, the selected infusion device displays (e.g., at a display screen) a confirmation request for the caregiver to confirm the selected infusion device should be ganged to the master infusion device as a slave infusion device (block 6924). If the caregiver does not confirm that the selected infusion device should be ganged to the master infusion device (block 6926: N), then the selected infusion device is not ganged to the master infusion device (block 6928). If, however, the caregiver does confirm that the selected infusion device should be ganged to the master infusion device (block 6926: Y), then the selected infusion device is ganged to the master infusion device (block 6930). The caregiver may gang multiple infusion devices to the master infusion devices. Accordingly, if the caregiver wishes to gang additional infusion devices to the master infusion device (block 6932: Y), the caregiver may repeat the steps above to gang additional infusion devices to the master infusion device. If the caregiver does not wish to gang additional infusion devices to the master infusion device (block 6932: N), or once the caregiver has ganged the desired number of infusion devices to the master infusion device, the caregiver may provide the infusion sequence configuration information to the master infusion device (block 6934). Once the caregiver has configured and confirmed the inter-device infusion sequence, the caregiver may initiate the infusion sequence and the master infusion device controls the infusion sequence across the ganged infusion devices (block 6936).



FIG. 70 depicts a flowchart of example method steps for designating a master infusion device for infusion devices ganged together via an interconnecting device. A set of infusion devices may be interconnected via an interconnecting device (block 7002). The lead infusion device at the interconnecting device may be identified (block 7004), e.g., the top-most or left-most infusion device mounted at the interconnecting device. The lead infusion device may be set as the master infusion device (block 7006) and one or more of the other infusion devices mounted at the interconnecting device may be designated as slave infusion devices to gang those infusion devices with the master infusion device (block 7008). The master infusion device may initiate an infusion sequence involving the ganged infusion devices (block 7010) and control the ganged infusion devices during the infusion sequence (block 7012).


While the slave infusion devices remain in signal communication with the master infusion device (block 7014: Y), the master infusion device may continue to control the ganged infusion devices during the infusion sequence (block 7012). If, however, the slave infusion devices lose the connection to the master infusion device and are no longer in signal communication with the master infusion device (block 7014: N), then the next sequential infusion device at the interconnecting device (e.g., the next top-most) may be identified (block 7016) and designated as the new master infusion device (block 7018). The new master infusion device may take over controlling the ganged infusion devices during the infusion sequence (block 7012).



FIG. 71 depicts a flowchart of example method steps for designating a master infusion device for infusion devices ganged together via wireless communications. A set of infusion devices in wireless signal communication with each other may be ganged together (block 7102), and a caregiver may configure a multi-step infusion sequence for the ganged infusion devices (block 7104). The caregiver may assign various steps of the multi-step infusion sequence to various infusion devices that have been ganged together (block 7106). The duration of each step may be calculate (block 7108), and the infusion device having the longest infusion duration may be designated as the master infusion device (block 7110). The other infusion devices may be designated as slave infusion devices for the master infusion device (block 7112).


During the infusion sequence, the master infusion device may control the slave infusion devices (block 7114). While the slave infusion devices remain in signal communication with the master infusion device (block 7116: Y), the master infusion device may continue to control the ganged infusion devices during the multi-step infusion sequence. If, however, the slave infusion devices lose the connection to the master infusion device and are no longer in signal communication with the master infusion device (block 7116: N), then the infusion device having the next longest infusion duration is identified (block 7118) and designated as the new master infusion device (block 7120). The new master infusion device may take over controlling the ganged infusion devices during the infusion sequence (block 7114).


It will be appreciated with the benefit of this disclosure that various combinations of the steps described above may be employed where the ganged together infusion devices include infusion devices that are in signal communication both wirelessly and via an interconnecting device. As an example, the ganged together infusion devices include infusion devices mounted at an interconnecting device as well as infusion devices that exchange communications wirelessly. In this example, the infusion devices at the interconnecting device may take precedence over the infusion devices ganged together wirelessly such that the lead infusion device at the interconnecting device may be designated the master infusion device. If the connection to the master infusion device is lost, the new master infusion device may be designated from the next sequential infusion device at the interconnecting device until connection with all infusion devices at the interconnecting device has been lost at which point, the new master infusion device may be the wirelessly communicating infusion device having the longest duration. If the set of ganged together infusion devices includes multiple interconnecting devices and connection to all infusion devices at one of the interconnecting devices has been lost, then the lead infusion device at the next sequential interconnecting device may be designated as the new master infusion device and so forth.



FIGS. 72A-72B depict another flowchart of example method steps for ganging together infusion devices that are interconnected via a medication management system.


Interconnecting infusion devices wirelessly, via an interconnecting device, or via a medication management system provides various advantages when performing infusions at a patient. Some example advantages include limiting the total infusion rate across each infusion device associated with a patient, tracking accumulated air across the infusion devices associated with a patient, choosing a connecting site for an infusion device and checking drug compatibility across the same connection site, and checking for duplicate drug selections across each infusion device associated with a patient. With respect to limiting the infusion rate, inter-device communication allows a caregiver or care facility (e.g., a hospital) to limit the total infusion rate across each infusion device associated with the patient to an infusion rate determined by the caregiver or care facility. The total infusion rate may be limited across each channel on a dual-channel infusion device or across each respective channel of multiple infusion devices. Potentially unsafe infusion rates may thus be identified and tracked. With respect to tracking accumulated air, the inter-device communication allows a caregiver or care facility to track the air that has been accumulated across all infusion device types associated with a patient, e.g., LVP, syringe, and PCA infusion device types. The interconnected infusion devices may provide an alarm when the accumulated air reaches an air accumulation threshold which may be set by the caregiver or care facility. A caregiver may also select a connection site for the infusion devices and initiate a drug compatibility check. As described above, a caregiver may be notified of any potential drug incompatibilities at a common connection site which the caregiver may override if needed. A caregiver may likewise initiate a duplicate drug selection check across infusion devices associated with a patient and receive notification of any duplicate drugs selected to be infused at the patient and again override if needed.


The drug duplication and compatibility checks may happen in the background as the caregiver continues programming the infusion sequence thus preventing delays in therapy in the case where there is no duplicate. When connected via an MMS, the duplicate drug check may be accomplished in various ways, e.g., 1) if the drug is being programmed for an inter-channel sequence then the infusion device checks the selected drug against the other selected drugs for all other steps in the therapy; 2) the infusion device sends a status message with the selected medication to the MMS which checks if the selected drug is programmed on other channels for the patient, and the MMS will respond with the results of the duplication check; 3) the infusion device sends the selected drug to the other infusers connected via an interconnecting device and the other infusion devices will respond with the results of the duplication check; 4) the infusion device polls nearby infusers wirelessly to check if they are associated to the same patient and, if so, the infusion device sends the selected drug to the other infusion devices associated with the patient. The other infusion devices may then respond with the results of the duplication check.


Similar techniques may be utilized to check for drug compatibility. An infusion device may likewise check for potential drug incompatibility in various ways, e.g., 1) the infusion device may send its currently programmed clinical care area (CCA) to the other infusion devices. If the other infusion devices are in the same CCA, the infusion device may send the programmed drug to the other infusion devices which may issue a response indicating that no compatibility issues exist or respond with the incompatible drug name; 2) the infusion device sends its currently programmed CCA to the other infusion devices, and if the other infusion devices are not in the same CCA, the infusion device sends a list of incompatible drugs for the programmed drug to the other infusion devices which issue a response indicating no compatibility issues exist or respond with the incompatible drug name; 3) the infusion device requests the drugs with which the other infusion devices are programmed and the first infusion device checks for compatibility against its drug library.


With respect to tracking accumulated air across each infusion device associated with a patient, if an MMS is present, the MMS may be configured to receive periodic status messages that include accumulated air values from infusion devices during an ongoing infusion. The MMS may aggregate the accumulated air values from the infusion devices associated with the patient and send the aggregated value to each infusion device in a response to the periodic status message or as a separate message. If one of the infusion devices associated with the patient detects accumulated air that exceeds the threshold for accumulated air, that infusion device will provide a notification or alarm. The infusion device may continue infusing based on criticality of the substance being infused or other drug library rules. The other associated infusion devices may continue infusing until they also detect accumulated air, at which point they will also provide a notification or alarm. The caregiver may then attend to the alarming infusion devices, which may include dismissing the alarm message, resetting the accumulated air value, or removing air from the infusion device. Once the caregiver resets the accumulated air value, the MMS may be notified via the status message and may disseminate the reset value to the associated infusion devices. If the MMS connection is lost, then the infusion devices may continue operating on the most recently received aggregate accumulated air value, adding to the value as it tracks air, if any. Each infusion device may provide a notification or alarm individually if it exceeds the accumulated air threshold. When the MMS connection is reestablished, the infusion devices may send their current accumulated air values to the MMS which may sum the accumulated air across all infusion devices from the previous aggregate value and disseminate that value to the associated infusion devices. The infusion devices may also be configured to connect locally to the other associated infusion devices to continue tracking the aggregate accumulated air. This may occur whether the MMS was originally present or not. If connected via an interconnecting device, the top-most infusion device may designated as the master infusion device as described above and may be responsible for computing the aggregate accumulated air value. If the infusion devices utilize point-to-point wireless communication, the infusion device having the longest infusion duration remaining may be designated the master infusion device and likewise be responsible for computing the accumulated air value. If the infusion devices were communicating locally and a connection to an MMS is established, the master infusion device may send its aggregated value to the MMS and the infusion devices which lost connection to the master infusion device, if any, may also send their accumulated air values. The MMS may then disseminate the new aggregate accumulated air value.


Limiting the total infusion rate across each infusion device associated with a patient may function in a fashion similar to that of tracking the accumulated air. The total infusion rate may be set by the caregiver, the care facility, or the CCA. If an MMS is present, the MMS may track the total infusion rate. If, however, an MMS is not present, then the infusion devices may communicate with one another to designate a master infusion device, and the master infusion device may track the total infusion rate.



FIG. 73 depicts a flowchart of example method steps for configuring an infusion at an infusion device. A first infusion of a first type may be initiated at an infusion device (block 7302). While the first infusion is infusing, the infusion device may receive, at an input device, input indicating a selection of a second infusion of a second type (block 7304). The infusion device may display, at an output device, a configurable parameter of the second infusion (block 7306). The infusion device may then receive, at the input device, input indicating a value for the configurable parameter (block 7308). The infusion device may then initiate the second infusion.



FIG. 74 depicts a flowchart of example method steps for configuring a sequence of infusion steps at an infusion device. An infusion device may initiate a first infusion step of an infusion (block 7402). While the first infusion step is being performed, the infusion device may receive, at an input device, input corresponding to a second infusion step (block 7404). The second infusion step may be configured based on the input received (block 7406), and the infusion device may initiate the second infusion step (block 7408).



FIG. 75 depicts a flowchart of example method steps for interconnecting multiple infusion devices and controlling the interconnected infusion devices from a master infusion device during an infusion. An infusion device may receive, via an input device, input corresponding to an infusion comprising a plurality of infusion steps (block 7502). The infusion device may establish a connection with at least one other infusion device via a communication interface to yield a plurality of interconnected infusion devices (block 7504). One of the interconnected infusion devices may be designated as a master infusion device (block 7506). During the infusion, the interconnected infusion devices may be controlled from the infusion device designated as the master infusion device (block 7508).


While the disclosure has been described with respect to specific examples including presently illustrative modes of carrying out the disclosure, a person having ordinary skill in the art, after review of the entirety disclosed herein, will appreciate that there are numerous variations and permutations of the above-described systems and techniques that fall within the spirit and scope of the disclosure.

Claims
  • 1. A method of performing an infusion comprising: receiving, at an input device of one of a plurality of infusion devices, input corresponding to an infusion comprising a plurality of infusion steps;establishing a wireless connection between at least two of the plurality of infusion devices to yield a plurality of interconnected infusion devices;designating one of the plurality of interconnected infusion devices as a master infusion device;controlling the plurality of interconnected infusion devices from the master infusion device during the infusion;determining, during the infusion, that the wireless connection to the master infusion device has been lost;designating another one of the plurality of interconnected infusion devices as a new master infusion device; andcontrolling the plurality of interconnected infusion devices from the new master infusion device during the infusion.
  • 2. The method of claim 1, wherein: a first one of the plurality of interconnected infusion devices is configured to perform a first infusion step of the infusion; anda second one of the plurality of interconnected infusion devices is configured to perform a second infusion step of the infusion.
  • 3. The method of claim 1, wherein: the interconnected infusion device designated as the master infusion device is the interconnected infusion device configured to perform an infusion step of the infusion that has a longest infusion duration.
  • 4. The method of claim 3, wherein: the interconnected infusion device designated as the new master infusion device is the interconnected infusion device configured to perform a remaining infusion step of the infusion that has the longest duration of one or more remaining infusion steps of the infusion.
  • 5. The method of claim 3, wherein: the plurality of interconnected infusion devices are interconnected in series at an interconnecting device; andthe interconnected infusion device designated as the master infusion device is the interconnected infusion device that is next in the series at the interconnecting device.
  • 6. The method of claim 1, wherein: the plurality of interconnected infusion devices are connected in series via an interconnecting device; andthe interconnected infusion device designated as the master infusion device is the interconnected infusion device that is first in the series at the interconnecting device.
  • 7. The method of claim 6, wherein: the interconnecting device is one of a backplane, a rack, or a dock.
  • 8. The method of claim 1, further comprising: polling one of the plurality of infusion devices from another one of the plurality of infusion devices; anddetermining whether the other infusion device is available to perform at least one of the plurality of infusion steps based on the poll.
  • 9. The method of claim 8, wherein: the polling comprises transmitting a message to the other infusion device that identifies a patient.
  • 10. The method of claim 1, further comprising: performing, before initiating the infusion, a safety check based on one or more substances the plurality of interconnected infusion devices are configured to infuse during the infusion.
  • 11. The method of claim 10, wherein: the safety check comprises at least one of a duplicability check and a compatibility check.
  • 12. The method of claim 1, further comprising: tracking a total amount of air that the plurality of interconnected infusion devices accumulate during the infusion; andproviding a notification responsive to determining that the total amount of air that has been accumulated exceeds an accumulated air threshold.
US Referenced Citations (1676)
Number Name Date Kind
3401337 Beusman et al. Sep 1968 A
3484681 Grady, Jr. et al. Dec 1969 A
3699320 Zimmerman et al. Oct 1972 A
3727074 Keller et al. Apr 1973 A
3731679 Wilhelmson et al. May 1973 A
3768084 Haynes Oct 1973 A
3770354 Tsuruta et al. Nov 1973 A
3778702 Finger Dec 1973 A
3806821 Niemeyer et al. Apr 1974 A
3838565 Carlyle Oct 1974 A
3854038 McKinley Dec 1974 A
3886459 Hufford et al. May 1975 A
3890554 Yoshitake et al. Jun 1975 A
3894431 Muston et al. Jul 1975 A
3898637 Wolstenholme Aug 1975 A
3901231 Olson Aug 1975 A
3909693 Yoshitake et al. Sep 1975 A
3910701 Henderson Oct 1975 A
3911343 Oster Oct 1975 A
3919608 Usami et al. Nov 1975 A
3921622 Cole Nov 1975 A
3930404 Ryden, Jr. Jan 1976 A
3933431 Trujillo et al. Jan 1976 A
3935876 Massie et al. Feb 1976 A
3944963 Hively Mar 1976 A
3966358 Heimes et al. Jun 1976 A
3971980 Jungfer et al. Jul 1976 A
3974681 Namery Aug 1976 A
3974683 Martin Aug 1976 A
3985467 Lefferson Oct 1976 A
3990444 Vial Nov 1976 A
3997888 Kremer Dec 1976 A
4005724 Courtot Feb 1977 A
4014206 Taylor Mar 1977 A
4038982 Burke Aug 1977 A
4039269 Pickering Aug 1977 A
4048474 Olesen Sep 1977 A
4049954 Da Costa Vieira et al. Sep 1977 A
4055175 Clemens et al. Oct 1977 A
4057228 Völker et al. Nov 1977 A
4068521 Cosentino et al. Jan 1978 A
4078562 Friedman Mar 1978 A
4089227 Falgari et al. May 1978 A
4094318 Burke Jun 1978 A
4105028 Sadlier et al. Aug 1978 A
4114144 Hyman Sep 1978 A
4151845 Clemens May 1979 A
4155362 Jess May 1979 A
4173224 Marx Nov 1979 A
4181610 Shintani et al. Jan 1980 A
4183244 Kohno et al. Jan 1980 A
4195515 Smoll Apr 1980 A
4210138 Jess et al. Jul 1980 A
4213454 Shim Jul 1980 A
4217993 Jess et al. Aug 1980 A
4240294 Grande Dec 1980 A
4240438 Updike et al. Dec 1980 A
4244365 McGill Jan 1981 A
4256437 Brown Mar 1981 A
4261356 Turner et al. Apr 1981 A
4264861 Radu et al. Apr 1981 A
4265240 Jenkins May 1981 A
4270532 Franetzki et al. Jun 1981 A
4277226 Archibald et al. Jul 1981 A
4278085 Shim Jul 1981 A
4280495 Lampert Jul 1981 A
4282872 Franetzki et al. Aug 1981 A
4286202 Clancy et al. Aug 1981 A
4290346 Bujan Sep 1981 A
4291692 Bowman et al. Sep 1981 A
4292405 Mascoli Sep 1981 A
4298357 Permic Nov 1981 A
4308866 Jeliffe Jan 1982 A
4312341 Zissimopoulos Jan 1982 A
4319568 Tregoning Mar 1982 A
4322201 Archibald Mar 1982 A
4323849 Smith Apr 1982 A
4324662 Schnell Apr 1982 A
4328800 Marx May 1982 A
4328801 Marx May 1982 A
4333045 Oltendorf Jun 1982 A
4343316 Jespersen Aug 1982 A
4344429 Gupton et al. Aug 1982 A
4346707 Whitney et al. Aug 1982 A
4360019 Portner et al. Nov 1982 A
4366384 Jensen Dec 1982 A
4367736 Gupton Jan 1983 A
4370983 Lichtenstein et al. Feb 1983 A
4373527 Fischell Feb 1983 A
4379452 DeVries Apr 1983 A
4381005 Bujan Apr 1983 A
4384578 Winkler May 1983 A
4385247 Satomi May 1983 A
4391598 Thompson Jul 1983 A
4392849 Petre et al. Jul 1983 A
4394862 Shim Jul 1983 A
4395259 Prestele et al. Jul 1983 A
4397194 Soltz Aug 1983 A
4399362 Cormier et al. Aug 1983 A
4407659 Adam Oct 1983 A
4411651 Schulman Oct 1983 A
4418565 St. John Dec 1983 A
4432699 Beckman et al. Feb 1984 A
4432761 Dawe Feb 1984 A
4432762 Dawe Feb 1984 A
4443218 Decant, Jr. et al. Apr 1984 A
4444546 Pazemenas Apr 1984 A
4447191 Bilstad et al. May 1984 A
4447224 Decant, Jr. et al. May 1984 A
4453931 Pastrone Jun 1984 A
4457751 Rodler Jul 1984 A
4463301 Moriguchi et al. Jul 1984 A
4464170 Clemens Aug 1984 A
4467654 Murakami et al. Aug 1984 A
4468222 Lundquist Aug 1984 A
4468601 Chamran et al. Aug 1984 A
4469481 Kobayashi Sep 1984 A
4475666 Bilbrey et al. Oct 1984 A
4475901 Kraegen et al. Oct 1984 A
4477756 Moriguchi Oct 1984 A
4479760 Bilstad et al. Oct 1984 A
4480218 Hair Oct 1984 A
4480483 McShane Nov 1984 A
4483202 Ogua et al. Nov 1984 A
4487601 Lindemann Dec 1984 A
4492909 Hartwig Jan 1985 A
4496346 Mosteller Jan 1985 A
4498843 Schneider et al. Feb 1985 A
4501531 Bilstad et al. Feb 1985 A
4504263 Steuer Mar 1985 A
4507112 Hillel Mar 1985 A
4510266 Eertink Apr 1985 A
4515584 Abe et al. May 1985 A
4519792 Dawe May 1985 A
4521212 Ruschke Jun 1985 A
4525163 Slavik et al. Jun 1985 A
4526568 Clemens et al. Jul 1985 A
4526574 Pekkarinen Jul 1985 A
4529401 Leslie et al. Jul 1985 A
4533350 Danby et al. Aug 1985 A
4543955 Schroeppel Oct 1985 A
4551134 Slavik et al. Nov 1985 A
4553958 LeCocq Nov 1985 A
4559036 Wunsch Dec 1985 A
4559037 Franetzki et al. Dec 1985 A
4559044 Robinson Dec 1985 A
4559454 Kramer Dec 1985 A
4565500 Jeensalute et al. Jan 1986 A
4583981 Urquhart et al. Apr 1986 A
4587473 Turvey May 1986 A
4607520 Dam Aug 1986 A
4617014 Cannon et al. Oct 1986 A
4624661 Arimond Nov 1986 A
4627835 Fenton, Jr. Dec 1986 A
4633878 Bombardieri Jan 1987 A
4634426 Kamen Jan 1987 A
4634427 Hannula et al. Jan 1987 A
4636144 Abe et al. Jan 1987 A
4637813 DeVries Jan 1987 A
4645489 Krumme Feb 1987 A
4648869 Bobo, Jr. Mar 1987 A
4652260 Fenton, Jr. et al. Mar 1987 A
4658244 Meijer Apr 1987 A
4668216 Martin May 1987 A
4668945 Aldrovandi et al. May 1987 A
4673334 Allington et al. Jun 1987 A
4673389 Archibald et al. Jun 1987 A
4676776 Howson et al. Jun 1987 A
4677359 Enami et al. Jun 1987 A
4678979 Hori Jul 1987 A
4678998 Muramatsu Jul 1987 A
4679562 Luksha Jul 1987 A
4683428 Gete Jul 1987 A
4685903 Cable et al. Aug 1987 A
4690673 Blomquist Sep 1987 A
4691153 Nishimura Sep 1987 A
4692145 Weyant Sep 1987 A
4696671 Epstein et al. Sep 1987 A
4697129 Enami et al. Sep 1987 A
4702675 Aldrovandi et al. Oct 1987 A
4705506 Archibald et al. Nov 1987 A
4710106 Iwata et al. Dec 1987 A
4714462 DiDomenico Dec 1987 A
4714463 Archibald et al. Dec 1987 A
4718576 Tamura et al. Jan 1988 A
4720636 Benner Jan 1988 A
4722224 Scheller et al. Feb 1988 A
4722734 Kolin Feb 1988 A
4731051 Fischell Mar 1988 A
4731057 Tanaka et al. Mar 1988 A
4737711 O'Hare Apr 1988 A
4739346 Buckley Apr 1988 A
4741732 Crankshaw et al. May 1988 A
4741736 Brown May 1988 A
4748857 Nakagawa Jun 1988 A
4751445 Sakai Jun 1988 A
4756706 Kerns et al. Jul 1988 A
4758228 Williams Jul 1988 A
4763525 Cobb Aug 1988 A
4764166 Spani et al. Aug 1988 A
4764697 Christiaens Aug 1988 A
4769001 Prince Sep 1988 A
4776842 Franetzki et al. Oct 1988 A
4781687 Wall Nov 1988 A
4784576 Bloom et al. Nov 1988 A
4785184 Bien et al. Nov 1988 A
4785799 Schoon et al. Nov 1988 A
4785969 McLaughlin Nov 1988 A
4786800 Kamen Nov 1988 A
4789014 DiGianfilippo Dec 1988 A
4797655 Orndal et al. Jan 1989 A
4803389 Ogawa et al. Feb 1989 A
4803625 Fu et al. Feb 1989 A
4818186 Pastrone et al. Apr 1989 A
4820281 Lawler Apr 1989 A
4821558 Pastrone et al. Apr 1989 A
4828545 Epstein et al. May 1989 A
4828693 Lindsay May 1989 A
4829448 Balding et al. May 1989 A
4838856 Mulreany et al. Jun 1989 A
4838857 Strowe et al. Jun 1989 A
4840542 Abbott Jun 1989 A
4842584 Pastrone et al. Jun 1989 A
4845487 Frantz et al. Jul 1989 A
4846792 Bobo et al. Jul 1989 A
4850805 Madsen et al. Jul 1989 A
4851755 Fincher Jul 1989 A
4854324 Hirschman et al. Aug 1989 A
4856339 Williams Aug 1989 A
4857048 Simons et al. Aug 1989 A
4857050 Lentz et al. Aug 1989 A
4858154 Anderson et al. Aug 1989 A
4863425 Slate et al. Sep 1989 A
4865584 Epstein et al. Sep 1989 A
4869722 Heyman Sep 1989 A
4874359 White et al. Oct 1989 A
4881413 Georgi et al. Nov 1989 A
4882575 Kawahara Nov 1989 A
4884013 Jackson et al. Nov 1989 A
4884065 Crouse et al. Nov 1989 A
4886422 Takeuchi et al. Dec 1989 A
4898576 Philip Feb 1990 A
4898578 Rubalcaba, Jr. Feb 1990 A
4906103 Kao Mar 1990 A
4908017 Howson et al. Mar 1990 A
4908019 Urquhart et al. Mar 1990 A
4910475 Lin Mar 1990 A
4919595 Likuski et al. Apr 1990 A
4919596 Slate et al. Apr 1990 A
4925444 Orkin et al. May 1990 A
4927411 Pastrone et al. May 1990 A
4930358 Motegi et al. Jun 1990 A
4936820 Dennehey Jun 1990 A
4936828 Chiang Jun 1990 A
4938079 Goldberg Jul 1990 A
4943279 Samiotes et al. Jul 1990 A
4946439 Eggers Aug 1990 A
4947856 Beard Aug 1990 A
4950235 Slate et al. Aug 1990 A
4950244 Fellingham Aug 1990 A
4959050 Bobo, Jr. Sep 1990 A
4966579 Polaschegg Oct 1990 A
4968941 Rogers Nov 1990 A
4972842 Korten et al. Nov 1990 A
4976687 Martin Dec 1990 A
4978335 Arthur, III Dec 1990 A
4979940 Lapp et al. Dec 1990 A
4981467 Bobo et al. Jan 1991 A
5000663 Gorton Mar 1991 A
5000739 Kulisz et al. Mar 1991 A
5006050 Cooke et al. Apr 1991 A
5010473 Jacobs Apr 1991 A
5014714 Millay et al. May 1991 A
5014798 Glynn May 1991 A
5018945 D'Silva May 1991 A
5026348 Venegas Jun 1991 A
5028857 Taghezout Jul 1991 A
5032112 Fairchild et al. Jul 1991 A
5034004 Crankshaw Jul 1991 A
5035143 Latimer et al. Jul 1991 A
5040699 Gangemi Aug 1991 A
5041086 Koenig et al. Aug 1991 A
5043706 Oliver Aug 1991 A
5045069 Imparato Sep 1991 A
5049047 Polaschegg et al. Sep 1991 A
5052230 Lang Oct 1991 A
5053747 Slate et al. Oct 1991 A
5055761 Mills Oct 1991 A
5056992 Simons Oct 1991 A
5058161 Weiss Oct 1991 A
5059171 Bridge Oct 1991 A
5063603 Burt Nov 1991 A
5064412 Henke et al. Nov 1991 A
5078683 Sancoff et al. Jan 1992 A
5084663 Olsson Jan 1992 A
5084828 Kaufman et al. Jan 1992 A
5088981 Howson et al. Feb 1992 A
5096385 Georgi et al. Mar 1992 A
5097505 Weiss Mar 1992 A
5100380 Epstein et al. Mar 1992 A
5102392 Sakai et al. Apr 1992 A
5103211 Daoud et al. Apr 1992 A
5104374 Bishko et al. Apr 1992 A
5108367 Epstein et al. Apr 1992 A
5109850 Blanco et al. May 1992 A
5116203 Nartwick et al. May 1992 A
5116312 Blakenship et al. May 1992 A
5116316 Sertic May 1992 A
5123275 Daoud et al. Jun 1992 A
5124627 Okada Jun 1992 A
5125499 Saathoff et al. Jun 1992 A
5131816 Brown Jul 1992 A
5132603 Yoshimoto Jul 1992 A
5153827 Coutre et al. Oct 1992 A
5158441 Aid Oct 1992 A
5161222 Montejo et al. Nov 1992 A
5174472 Raque et al. Dec 1992 A
5176631 Koenig Jan 1993 A
5176646 Kuroda Jan 1993 A
5179340 Rogers Jan 1993 A
5180287 Natwick et al. Jan 1993 A
5181910 Scanlon Jan 1993 A
5186057 Everhart Feb 1993 A
5188603 Vaillancourt Feb 1993 A
5190522 Wocicki et al. Mar 1993 A
5191795 Fellingham et al. Mar 1993 A
5192340 Grant et al. Mar 1993 A
5194796 Domeki et al. Mar 1993 A
5198776 Carr Mar 1993 A
5200090 Ford Apr 1993 A
5205819 Ross et al. Apr 1993 A
5206522 Danby et al. Apr 1993 A
5207642 Orkin et al. May 1993 A
5211626 Frank et al. May 1993 A
5213573 Sorich et al. May 1993 A
5215450 Tamari Jun 1993 A
5216597 Beckers Jun 1993 A
5219099 Spence et al. Jun 1993 A
5219327 Okada Jun 1993 A
5221268 Barton et al. Jun 1993 A
5229713 Bullock et al. Jul 1993 A
5232476 Grant Aug 1993 A
5233571 Wirtschafter Aug 1993 A
5237309 Frantz et al. Aug 1993 A
5242406 Gross et al. Sep 1993 A
5242408 Jhuboo et al. Sep 1993 A
5243982 Möstl et al. Sep 1993 A
5244463 Cordner, Jr. et al. Sep 1993 A
5244568 Lindsay et al. Sep 1993 A
5254096 Rondelet et al. Oct 1993 A
5256155 Yerlikaya et al. Oct 1993 A
5256156 Kern et al. Oct 1993 A
5256157 Samiotes et al. Oct 1993 A
5260665 Goldberg Nov 1993 A
5257206 Hanson Dec 1993 A
5267980 Dirr et al. Dec 1993 A
5274316 Evans et al. Dec 1993 A
5276610 Maeda et al. Jan 1994 A
5280728 Sato et al. Jan 1994 A
5283510 Tamaki et al. Feb 1994 A
5287851 Beran et al. Feb 1994 A
5292306 Wynkoop et al. Mar 1994 A
5295967 Rondelet et al. Mar 1994 A
5298021 Sherer Mar 1994 A
5303585 Lichte Apr 1994 A
5304126 Epstein et al. Apr 1994 A
5304216 Wallace Apr 1994 A
5308333 Skakoon May 1994 A
5317506 Coutre et al. May 1994 A
5319363 Welch et al. Jun 1994 A
5319979 Abrahamson Jun 1994 A
5321392 Skakoon et al. Jun 1994 A
5325170 Bornhop Jun 1994 A
5325728 Zimmerman et al. Jul 1994 A
5328460 Lord et al. Jul 1994 A
5330634 Wong et al. Jul 1994 A
5333497 Braend et al. Aug 1994 A
5336051 Tamari Aug 1994 A
5338157 Blomquist Aug 1994 A
5342298 Michaels Aug 1994 A
5343734 Maeda et al. Sep 1994 A
5343885 Grant Sep 1994 A
5346466 Yerlikaya et al. Sep 1994 A
5356378 Doan et al. Oct 1994 A
5359271 Husher Oct 1994 A
D352778 Irvin et al. Nov 1994 S
5364346 Schrezenmeir Nov 1994 A
5366346 Danby Nov 1994 A
5368562 Blomquist et al. Nov 1994 A
5374865 Yoshimura et al. Dec 1994 A
5376070 Purvis et al. Dec 1994 A
5378231 Johnson et al. Jan 1995 A
5382232 Hague et al. Jan 1995 A
5383369 Khuri-Yakub et al. Jan 1995 A
5389071 Kawahara et al. Feb 1995 A
5389078 Zalesky et al. Feb 1995 A
5392638 Kawahara Feb 1995 A
5394732 Johnson et al. Mar 1995 A
5395320 Padda et al. Mar 1995 A
5399171 Bowman et al. Mar 1995 A
5406954 Tomita Apr 1995 A
5408326 Priestley Apr 1995 A
5415528 Ogden et al. May 1995 A
5417119 Smoll May 1995 A
5417222 Dempsey et al. May 1995 A
5417395 Fowler et al. May 1995 A
5418443 Kikuchi May 1995 A
5421208 Packard et al. Jun 1995 A
5423748 Uhala Jun 1995 A
5423749 Merte et al. Jun 1995 A
5423759 Campbell Jun 1995 A
5428284 Kaneda et al. Jun 1995 A
5429485 Dodge Jul 1995 A
5429601 Conley Jul 1995 A
5429602 Hauser Jul 1995 A
5431627 Pastrone et al. Jul 1995 A
5434508 Ishida Jul 1995 A
5437624 Langley et al. Aug 1995 A
5444316 Ohya et al. Aug 1995 A
5444378 Rogers Aug 1995 A
5445621 Poli et al. Aug 1995 A
5450758 Smoll Sep 1995 A
5451881 Finger Sep 1995 A
5455423 Mount et al. Oct 1995 A
5455851 Chaco et al. Oct 1995 A
5463906 Spani et al. Nov 1995 A
5464392 Epstein et al. Nov 1995 A
5465082 Chaco Nov 1995 A
5469851 Lipschutz Nov 1995 A
5473948 Moss et al. Dec 1995 A
5480294 Di Perna et al. Jan 1996 A
5482438 Anderson et al. Jan 1996 A
5485408 Blomquist Jan 1996 A
5486286 Peterson et al. Jan 1996 A
5489265 Montalvo et al. Feb 1996 A
5495566 Kwatinetz Feb 1996 A
5496273 Pastrone et al. Mar 1996 A
5505696 Miki Apr 1996 A
5505828 Wong et al. Apr 1996 A
5507288 Bocker et al. Apr 1996 A
5507412 Ebert et al. Apr 1996 A
5520637 Pager et al. May 1996 A
5522798 Johnson et al. Jun 1996 A
5522799 Furukawa Jun 1996 A
5527630 Nagata Jun 1996 A
5533389 Kamen et al. Jul 1996 A
5537853 Finburgh et al. Jul 1996 A
5542040 Chang et al. Jul 1996 A
5545140 Conero et al. Aug 1996 A
5547470 Johnson et al. Aug 1996 A
5551850 Williamson et al. Sep 1996 A
5554013 Owens et al. Sep 1996 A
5554115 Thomas et al. Sep 1996 A
5558638 Evers et al. Sep 1996 A
5562615 Nassif Oct 1996 A
5563486 Yamamoto et al. Oct 1996 A
5572105 Nojima et al. Nov 1996 A
5573502 LeCocq et al. Nov 1996 A
5583280 Mo et al. Dec 1996 A
5584667 Davis Dec 1996 A
5584806 Amano Dec 1996 A
5586868 Lawless et al. Dec 1996 A
5590653 Aida et al. Jan 1997 A
5594786 Chaco et al. Jan 1997 A
5600073 Hill Feb 1997 A
5601420 Warner et al. Feb 1997 A
5609575 Larson et al. Mar 1997 A
5609576 Voss Mar 1997 A
5611784 Barresi et al. Mar 1997 A
5616124 Hague et al. Apr 1997 A
5620312 Hyman et al. Apr 1997 A
5620608 Rosa et al. Apr 1997 A
5626140 Feldman et al. May 1997 A
5626151 Linden May 1997 A
5626563 Dodge et al. May 1997 A
5627443 Kimura et al. May 1997 A
5628309 Brown May 1997 A
5628731 Dodge et al. May 1997 A
5630710 Tune et al. May 1997 A
5634896 Bryant et al. Jun 1997 A
5637095 Nason et al. Jun 1997 A
5640075 Brasseur et al. Jun 1997 A
5640150 Atwater Jun 1997 A
5643212 Coutre et al. Jul 1997 A
5648710 Ikeda Jul 1997 A
5649536 Ogura et al. Jul 1997 A
5651775 Walker et al. Jul 1997 A
5657000 Ellingboe Aug 1997 A
5658133 Anderson et al. Aug 1997 A
5658250 Blomquist et al. Aug 1997 A
5659234 Cresens Aug 1997 A
5661245 Svoboda et al. Aug 1997 A
5662612 Niehoff Sep 1997 A
5665065 Colman et al. Sep 1997 A
5669877 Blomquist Sep 1997 A
5672154 Sillén et al. Sep 1997 A
5672832 Cucci et al. Sep 1997 A
5681285 Ford et al. Oct 1997 A
5681286 Niehoff Oct 1997 A
5685844 Marttila Nov 1997 A
5685866 Lopez Nov 1997 A
5687717 Halpern et al. Nov 1997 A
5689229 Chaco et al. Nov 1997 A
5691613 Gutwillinger Nov 1997 A
5695464 Viallet Dec 1997 A
5695473 Olsen Dec 1997 A
5697899 Hillman et al. Dec 1997 A
5697916 Schraga Dec 1997 A
5712795 Layman et al. Jan 1998 A
5713856 Eggers et al. Feb 1998 A
5714691 Hill Feb 1998 A
5718562 Lawless et al. Feb 1998 A
5718569 Holst Feb 1998 A
5720721 Dumas et al. Feb 1998 A
5722417 Rudolph Mar 1998 A
5728074 Castellano et al. Mar 1998 A
5728948 Bignell et al. Mar 1998 A
5733257 Stemby Mar 1998 A
5733259 Valcke et al. Mar 1998 A
5734464 Gibbs Mar 1998 A
5738659 Neer et al. Apr 1998 A
5743856 Oka et al. Apr 1998 A
5744027 Connell et al. Apr 1998 A
5744929 Miyazaki Apr 1998 A
5745378 Barker et al. Apr 1998 A
5752813 Tyner et al. May 1998 A
5752918 Fowler et al. May 1998 A
5752919 Schrimpf May 1998 A
5755691 Hilborne May 1998 A
5758643 Wong et al. Jun 1998 A
5761072 Bardsley, Jr. et al. Jun 1998 A
5764034 Bowman et al. Jun 1998 A
5766155 Hyman et al. Jun 1998 A
5772635 Dastur et al. Jun 1998 A
5778256 Darbee Jul 1998 A
5781442 Engleson et al. Jul 1998 A
5782805 Meinzer et al. Jul 1998 A
5788669 Peterson Aug 1998 A
5788674 McWilliams Aug 1998 A
5789923 Shimoyama et al. Aug 1998 A
5792069 Greenwald et al. Aug 1998 A
5793211 Shimoyama et al. Aug 1998 A
5795327 Wilson et al. Aug 1998 A
5798934 Saigo et al. Aug 1998 A
5800387 Duffy et al. Sep 1998 A
5803712 Davis et al. Sep 1998 A
5803917 Butterfield Sep 1998 A
5805455 Lipps Sep 1998 A
5807322 Lindsey et al. Sep 1998 A
5810770 Chin et al. Sep 1998 A
5813972 Nazarian et al. Sep 1998 A
5814004 Tamari Sep 1998 A
5814015 Gargano et al. Sep 1998 A
5816779 Lawless et al. Oct 1998 A
5822715 Worthington et al. Oct 1998 A
5827179 Lichter et al. Oct 1998 A
5827223 Butterfield Oct 1998 A
5832448 Brown Nov 1998 A
5836910 Duffy et al. Nov 1998 A
5841261 Nojima et al. Nov 1998 A
5841284 Takahashi Nov 1998 A
5843035 Bowman Dec 1998 A
5848971 Fowler et al. Dec 1998 A
5850344 Conkright Dec 1998 A
5857843 Leason et al. Jan 1999 A
5864330 Haynes Jan 1999 A
5865805 Ziemba Feb 1999 A
5867821 Ballantyne et al. Feb 1999 A
5871465 Vasko Feb 1999 A
5872453 Shimoyama et al. Feb 1999 A
5875195 Dixon Feb 1999 A
5882300 Malinouskas et al. Mar 1999 A
5882339 Beiser et al. Mar 1999 A
5885245 Lynch et al. Mar 1999 A
5889379 Yanagi et al. Mar 1999 A
5891051 Han et al. Apr 1999 A
5894209 Takagi et al. Apr 1999 A
5897493 Brown Apr 1999 A
5897498 Canfield, II et al. Apr 1999 A
5898292 Takemoto et al. Apr 1999 A
5899665 Makino et al. May 1999 A
5901150 Jhuboo et al. May 1999 A
5904666 DeDecker et al. May 1999 A
5904668 Hyman et al. May 1999 A
5905207 Schalk May 1999 A
5906598 Giesier May 1999 A
5910252 Truitt et al. Jun 1999 A
5915240 Karpf Jun 1999 A
5920263 Huttenhoff et al. Jul 1999 A
5923159 Ezell Jul 1999 A
5924074 Evans Jul 1999 A
5927349 Martucci Jul 1999 A
5932119 Kaplan et al. Aug 1999 A
5932987 McLoughlin Aug 1999 A
5935066 Harris Aug 1999 A
5935099 Peterson et al. Aug 1999 A
5935106 Olsen Aug 1999 A
5938634 Packard Aug 1999 A
5938636 Kramer et al. Aug 1999 A
5941846 Duffy et al. Aug 1999 A
5944660 Kimball et al. Aug 1999 A
5947911 Wong et al. Sep 1999 A
5954527 Jhuboo et al. Sep 1999 A
5954696 Ryan et al. Sep 1999 A
5956023 Lyle et al. Sep 1999 A
5956501 Brown Sep 1999 A
5957885 Bollish et al. Sep 1999 A
5957890 Mann et al. Sep 1999 A
5971594 Sahai et al. Oct 1999 A
5973497 Bergk et al. Oct 1999 A
5975081 Hood et al. Nov 1999 A
5989222 Cole et al. Nov 1999 A
5990838 Burns et al. Nov 1999 A
5991525 Shah et al. Nov 1999 A
5993393 Ryan et al. Nov 1999 A
5994876 Canny et al. Nov 1999 A
5997476 Brown Dec 1999 A
6000828 Leet Dec 1999 A
6003006 Colella et al. Dec 1999 A
6003388 Oeftering Dec 1999 A
6012034 Hamparian et al. Jan 2000 A
6017318 Gauthier et al. Jan 2000 A
6017493 Cambron Jan 2000 A
6021392 Lester et al. Feb 2000 A
6023977 Langdon et al. Feb 2000 A
6024539 Blomquist Feb 2000 A
6027441 Cantu Feb 2000 A
6028412 Shine et al. Feb 2000 A
6032676 Moore Mar 2000 A
6033561 Schoendorfer Mar 2000 A
6036017 Bayliss, IV Mar 2000 A
6068612 Bowman May 2000 A
6068615 Brown et al. May 2000 A
6073106 Rozen et al. Jun 2000 A
6077246 Kullas et al. Jun 2000 A
6083206 Molko Jul 2000 A
6089104 Chang Jul 2000 A
6104295 Gaisser et al. Aug 2000 A
6110152 Kovelman Aug 2000 A
6110153 Davis Aug 2000 A
RE36871 Epstein et al. Sep 2000 E
6120459 Nitzan et al. Sep 2000 A
6122536 Sun et al. Sep 2000 A
6142008 Cole et al. Nov 2000 A
6150942 O'Brien Nov 2000 A
6157914 Seto et al. Dec 2000 A
6158288 Smith Dec 2000 A
6158965 Butterfield et al. Dec 2000 A
6159147 Lichter et al. Dec 2000 A
6159186 Wickham et al. Dec 2000 A
6164921 Moubayed et al. Dec 2000 A
6168561 Cantu Jan 2001 B1
6178827 Feller Jan 2001 B1
6182667 Hanks et al. Feb 2001 B1
6186141 Pike et al. Feb 2001 B1
6189105 Lopes Feb 2001 B1
6192752 Blaine Feb 2001 B1
6195589 Ketcham Feb 2001 B1
6202711 Martucci Mar 2001 B1
6203528 Deckert Mar 2001 B1
6208107 Maske et al. Mar 2001 B1
6212936 Meisberger Apr 2001 B1
6213972 Butterfield Apr 2001 B1
6231320 Lawless et al. May 2001 B1
6234176 Domae et al. May 2001 B1
6236326 Murphy et al. May 2001 B1
6237398 Porat et al. May 2001 B1
6241704 Peterson et al. Jun 2001 B1
6248067 Causey, III et al. Jun 2001 B1
6250132 Drzewiecki Jun 2001 B1
6259355 Chaco et al. Jul 2001 B1
6259587 Sheldon et al. Jul 2001 B1
6261065 Nayak Jul 2001 B1
6262946 Khuri-Yakub et al. Jul 2001 B1
6267559 Mossman et al. Jul 2001 B1
6267725 Dubberstein et al. Jul 2001 B1
6269340 Ford et al. Jul 2001 B1
6270455 Brown Aug 2001 B1
6271813 Palalau Aug 2001 B1
6277072 Bardy Aug 2001 B1
6277099 Strowe et al. Aug 2001 B1
6280380 Bardy Aug 2001 B1
6280391 Olson et al. Aug 2001 B1
6280408 Sipin Aug 2001 B1
6283761 Joao Sep 2001 B1
6285155 Maske et al. Sep 2001 B1
6312378 Bardy Nov 2001 B1
6322516 Masuda et al. Nov 2001 B1
6330351 Yasunaga Dec 2001 B1
6336053 Beatty Jan 2002 B1
6337675 Toffolo et al. Jan 2002 B1
6345539 Rawes et al. Feb 2002 B1
6347553 Morris et al. Feb 2002 B1
6349740 Cho et al. Feb 2002 B1
6358225 Butterfield Mar 2002 B1
6358387 Kopf-Sill et al. Mar 2002 B1
6362591 Moberg Mar 2002 B1
6385505 Lipps May 2002 B1
6386050 Yin et al. May 2002 B1
6394958 Bratteli et al. May 2002 B1
6396583 Clare May 2002 B1
6398760 Danby Jun 2002 B1
6405076 Taylor et al. Jun 2002 B1
6408679 Kline-Schoder et al. Jun 2002 B1
6413238 Maget Jul 2002 B1
6416291 Butterfield et al. Jul 2002 B1
6418334 Unger et al. Jul 2002 B1
6418535 Kulakowski et al. Jul 2002 B1
6445053 Cho Sep 2002 B1
6456245 Crawford Sep 2002 B1
6457346 Kline-Schoder et al. Oct 2002 B1
6463785 Kline-Schoder et al. Oct 2002 B1
6467331 Kline-Schoder et al. Oct 2002 B1
6468242 Wilson et al. Oct 2002 B1
6475178 Krajewski Nov 2002 B1
6481980 Vandlik Nov 2002 B1
6482158 Mault Nov 2002 B2
6482185 Hartmann Nov 2002 B1
6485263 Bryant et al. Nov 2002 B1
6485418 Yasushi et al. Nov 2002 B2
6485465 Moberg et al. Nov 2002 B2
6487916 Gomm et al. Dec 2002 B1
6489896 Platt Dec 2002 B1
6494694 Lawless et al. Dec 2002 B2
6494831 Koritzinsky Dec 2002 B1
6497680 Holst et al. Dec 2002 B1
6503221 Briggs Jan 2003 B1
6512944 Kovtun et al. Jan 2003 B1
6516667 Broad et al. Feb 2003 B1
6517482 Eiden et al. Feb 2003 B1
6519569 White et al. Feb 2003 B1
6529751 Van Driel et al. Mar 2003 B1
6531708 Malmstrom Mar 2003 B1
6539315 Adams et al. Mar 2003 B1
6540672 Simonsen et al. Apr 2003 B1
6544212 Galley et al. Apr 2003 B2
6544228 Heitmeier Apr 2003 B1
6558125 Futterknecht May 2003 B1
6558351 Steil et al. May 2003 B1
6562012 Brown et al. May 2003 B1
6564825 Lowery et al. May 2003 B2
6565509 Say et al. May 2003 B1
6568416 Tucker et al. May 2003 B2
6572542 Houben et al. Jun 2003 B1
6572545 Knobbe et al. Jun 2003 B2
6572576 Brugger et al. Jun 2003 B2
6578422 Lam et al. Jun 2003 B2
6578435 Gould et al. Jun 2003 B2
6581117 Klein et al. Jun 2003 B1
RE38189 Walker et al. Jul 2003 E
6585675 O'Mahony et al. Jul 2003 B1
6589229 Connelly et al. Jul 2003 B1
6589792 Malachowski Jul 2003 B1
6599281 Struys et al. Jul 2003 B1
6599282 Burko Jul 2003 B2
6602191 Quy Aug 2003 B2
6605072 Struys et al. Aug 2003 B2
6606047 Börjesson et al. Aug 2003 B1
6609047 Lipps Aug 2003 B1
6615674 Ohnishi Sep 2003 B2
6616633 Butterfield et al. Sep 2003 B1
6617564 Ockerse et al. Sep 2003 B2
6618916 Eberle et al. Sep 2003 B1
6622542 Derek Sep 2003 B2
6622561 Lam et al. Sep 2003 B2
D481121 Evans Oct 2003 S
6629449 Kline-Schoder et al. Oct 2003 B1
6634233 He Oct 2003 B2
6640246 Gardy, Jr. et al. Oct 2003 B1
6641533 Causey, III et al. Nov 2003 B2
6641541 Lovett et al. Nov 2003 B1
6648861 Platt et al. Nov 2003 B2
6652455 Kocher Nov 2003 B1
6653937 Nelson et al. Nov 2003 B2
6659980 Moberg et al. Dec 2003 B2
D485356 Evans Jan 2004 S
6685668 Cho et al. Feb 2004 B1
6685678 Evans et al. Feb 2004 B2
6689069 Bratteli et al. Feb 2004 B2
6689091 Bui et al. Feb 2004 B2
6692241 Watanabe et al. Feb 2004 B2
6716004 Vandlik Apr 2004 B2
6719535 Rakestraw et al. Apr 2004 B2
6721582 Trepagnier et al. Apr 2004 B2
6722211 Ciobanu et al. Apr 2004 B1
6725200 Rost Apr 2004 B1
6725721 Venczel Apr 2004 B2
6731989 Engleson et al. May 2004 B2
6732595 Lynnworth May 2004 B2
6738052 Manke et al. May 2004 B1
6740072 Starkweather et al. May 2004 B2
6741212 Kralovec et al. May 2004 B2
6748808 Lam et al. Jun 2004 B2
6749403 Bryant et al. Jun 2004 B2
6752787 Causey, III et al. Jun 2004 B1
6753842 Williams et al. Jun 2004 B1
6759007 Westberg Jul 2004 B1
6760643 Lipps Jul 2004 B2
6768920 Lange Jul 2004 B2
6773412 O'Mahony Aug 2004 B2
6780156 Haueter et al. Aug 2004 B2
6783328 Lucke et al. Aug 2004 B2
6785573 Kovtun et al. Aug 2004 B2
6786885 Hochman et al. Sep 2004 B2
6789426 Yaralioglu et al. Sep 2004 B2
6790198 White et al. Sep 2004 B1
6793625 Cavallaro et al. Sep 2004 B2
6801227 Bocionek et al. Oct 2004 B2
6805671 Stergiopoulos et al. Oct 2004 B2
6807965 Hickle Oct 2004 B1
6809653 Mann et al. Oct 2004 B1
6813964 Clark et al. Nov 2004 B1
6814547 Childers Nov 2004 B2
6824528 Faries Nov 2004 B1
6830558 Flaherty et al. Dec 2004 B2
6840113 Fukumura et al. Jan 2005 B2
6846161 Kline Jan 2005 B2
6852094 Beck Feb 2005 B2
6852104 Blomquist Feb 2005 B2
6854338 Khuri-Yakub et al. Feb 2005 B2
6857318 Silber et al. Feb 2005 B1
6869425 Briggs et al. Mar 2005 B2
6873268 Lebel et al. Mar 2005 B2
6883376 He Apr 2005 B2
6885881 Leonhardt Apr 2005 B2
6887216 Hochman et al. May 2005 B2
6898301 Iwanaga May 2005 B2
6907361 Molenaar Jun 2005 B2
6907792 Ohnishi Jun 2005 B2
6915170 Engleson et al. Jul 2005 B2
6920795 Bischoff et al. Jul 2005 B2
6923763 Kovatchev et al. Aug 2005 B1
6928338 Buchser et al. Aug 2005 B1
6929619 Fago et al. Aug 2005 B2
6929751 Bowman Aug 2005 B2
6932114 Sparks Aug 2005 B2
6932796 Sage et al. Aug 2005 B2
6935192 Sobek et al. Aug 2005 B2
6936029 Mann et al. Aug 2005 B2
6941005 Lary et al. Sep 2005 B2
6942636 Holst et al. Sep 2005 B2
6945954 Hochman et al. Sep 2005 B2
6958705 Lebel et al. Oct 2005 B2
6964204 Clark et al. Nov 2005 B2
6973374 Ader Dec 2005 B2
6974437 Lebel et al. Dec 2005 B2
6975922 Duncan et al. Dec 2005 B2
6978779 Haveri et al. Dec 2005 B2
6979326 Mann et al. Dec 2005 B2
6981960 Cho et al. Jan 2006 B2
6984218 Nayak et al. Jan 2006 B2
6985768 Hemming et al. Jan 2006 B2
6985870 Martucci et al. Jan 2006 B2
6986347 Hickle Jan 2006 B2
6986753 Bui Jan 2006 B2
6997905 Gillespie, Jr. et al. Feb 2006 B2
6997920 Mann et al. Feb 2006 B2
7006005 Nazarian et al. Feb 2006 B2
7017623 Tribble et al. Mar 2006 B2
7021148 Kuhn Apr 2006 B2
7025743 Mann et al. Apr 2006 B2
7029455 Flaherty Apr 2006 B2
7029456 Ware et al. Apr 2006 B2
7059184 Kanouda et al. Jun 2006 B2
7060059 Keith et al. Jun 2006 B2
7069793 Ishikawa et al. Jul 2006 B2
7072725 Bristol et al. Jul 2006 B2
7074209 Evans et al. Jul 2006 B2
7080557 Adnan Jul 2006 B2
7082843 Clark et al. Aug 2006 B2
7087444 Wong et al. Aug 2006 B2
7092796 Vanderveen Aug 2006 B2
7092797 Gaines et al. Aug 2006 B2
7093502 Kupnik et al. Aug 2006 B2
7096729 Repko et al. Aug 2006 B2
7103419 Engleson et al. Sep 2006 B2
7104763 Bouton et al. Sep 2006 B2
7104769 Davis Sep 2006 B2
7108680 Rohr et al. Sep 2006 B2
7109878 Mann et al. Sep 2006 B2
7115113 Evans et al. Oct 2006 B2
7117041 Engleson et al. Oct 2006 B2
7137964 Flaherty Nov 2006 B2
7141037 Butterfield et al. Nov 2006 B2
7152490 Freund, Jr. et al. Dec 2006 B1
7154397 Zerhusen et al. Dec 2006 B2
7161488 Frasch Jan 2007 B2
7162290 Levin Jan 2007 B1
7162927 Selvan et al. Jan 2007 B1
7171277 Engleson et al. Jan 2007 B2
7171992 DiGianfilippo et al. Feb 2007 B2
7174789 Orr et al. Feb 2007 B2
7185288 McKeever Feb 2007 B2
7197943 Lee et al. Apr 2007 B2
7201734 Hickle Apr 2007 B2
7204823 Estes et al. Apr 2007 B2
7206715 Vanderveen et al. Apr 2007 B2
7213009 Pestotnik May 2007 B2
7220240 Struys et al. May 2007 B2
7229430 Hickle et al. Jun 2007 B2
7230529 Ketcherside Jun 2007 B2
7232430 Carlisle Jun 2007 B2
7238164 Childers et al. Jul 2007 B2
7247154 Hickle Jul 2007 B2
7253779 Greer et al. Aug 2007 B2
7254425 Lowery et al. Aug 2007 B2
7258534 Fathallah et al. Aug 2007 B2
7267664 Rizzo Sep 2007 B2
7267665 Steil et al. Sep 2007 B2
7272529 Hogan et al. Sep 2007 B2
7278983 Ireland et al. Oct 2007 B2
7291123 Baraldi et al. Nov 2007 B2
7293461 Gimdt Nov 2007 B1
7294109 Lovett et al. Nov 2007 B2
7296482 Schaffer et al. Nov 2007 B2
7300418 Zaleski Nov 2007 B2
7305883 Khuri-Yakub et al. Dec 2007 B2
7327273 Hung et al. Feb 2008 B2
7338470 Katz Mar 2008 B2
7343224 DiGianfilippo et al. Mar 2008 B2
7347836 Peterson et al. Mar 2008 B2
7347854 Shelton et al. Mar 2008 B2
7354420 Steil et al. Apr 2008 B2
7356382 Vanderveen Apr 2008 B2
7360999 Nelson et al. Apr 2008 B2
7364562 Braig et al. Apr 2008 B2
7367942 Grage et al. May 2008 B2
7369948 Ferenczi et al. May 2008 B1
7384410 Eggers et al. Jun 2008 B2
7397166 Morgan et al. Jul 2008 B1
7398183 Holland et al. Jul 2008 B2
7399277 Saidara et al. Jul 2008 B2
7402153 Steil et al. Jul 2008 B2
7402154 Mendez Jul 2008 B2
7407489 Mendez Aug 2008 B2
7414534 Kroll et al. Aug 2008 B1
7415895 Kurisaki et al. Aug 2008 B2
7426443 Simon Sep 2008 B2
7430675 Lee et al. Sep 2008 B2
7447566 Knauper et al. Nov 2008 B2
7447643 Olson Nov 2008 B1
7452190 Bouton et al. Nov 2008 B2
7454314 Holland et al. Nov 2008 B2
7471994 Ford et al. Dec 2008 B2
7477997 Kaplit Jan 2009 B2
7482818 Greenwald et al. Jan 2009 B2
7483756 Engleson et al. Jan 2009 B2
7490021 Holland et al. Feb 2009 B2
7491187 Van Den Berghe et al. Feb 2009 B2
7503903 Carlisle et al. Mar 2009 B2
7517332 Tonelli et al. Apr 2009 B2
7523401 Aldridge Apr 2009 B1
7545075 Huang et al. Jun 2009 B2
7556616 Fathallah et al. Jul 2009 B2
7561986 Vanderveen et al. Jul 2009 B2
7571024 Duncan et al. Aug 2009 B2
7605730 Tomioka et al. Oct 2009 B2
7614310 Konzelmann Nov 2009 B2
7645258 White et al. Jan 2010 B2
7654127 Krulevitch et al. Feb 2010 B2
7657443 Crass Feb 2010 B2
7668731 Martucci et al. Feb 2010 B2
7678048 Urbano et al. Mar 2010 B1
7693697 Westenskow et al. Apr 2010 B2
7699806 Ware et al. Apr 2010 B2
7705727 Pestotnik Apr 2010 B2
7766873 Moberg et al. Aug 2010 B2
7775126 Eckhardt Aug 2010 B2
7775127 Wade Aug 2010 B2
7785284 Baralsi et al. Aug 2010 B2
7785313 Mastrototaro Aug 2010 B2
7786909 Udupa et al. Aug 2010 B2
7806886 Kanderian, Jr. et al. Oct 2010 B2
7826981 Goode, Jr. et al. Nov 2010 B2
7847276 Carlisle Dec 2010 B2
7860583 Condurso et al. Dec 2010 B2
7871394 Halbert et al. Jan 2011 B2
7876443 Bernacki Jan 2011 B2
7895053 Holland et al. Feb 2011 B2
7895882 Carlisle Mar 2011 B2
7896834 Smisson, III Mar 2011 B2
7896842 Palmroos et al. Mar 2011 B2
7905710 Wang et al. Mar 2011 B2
7933780 de la Huerga Apr 2011 B2
7945452 Fathallah et al. May 2011 B2
7976508 Hoag Jul 2011 B2
7981073 Mollstam Jul 2011 B2
7981082 Wang et al. Jul 2011 B2
7998134 Fangrow Aug 2011 B2
8002736 Patrick et al. Aug 2011 B2
8034020 Dewey Oct 2011 B2
8038593 Friedman et al. Oct 2011 B2
8065161 Howard et al. Nov 2011 B2
8067760 Carlisle Nov 2011 B2
8075514 Butterfield et al. Dec 2011 B2
8075546 Carlisle et al. Dec 2011 B2
8078983 Davis et al. Dec 2011 B2
8121857 Galasso et al. Feb 2012 B2
8149131 Blomquist Apr 2012 B2
8175668 Nabutovsky et al. May 2012 B1
8177739 Cartledge et al. May 2012 B2
8180440 McCombie et al. May 2012 B2
8185322 Schroeder et al. May 2012 B2
8197444 Bazargan et al. Jun 2012 B1
8219413 Martinez et al. Jul 2012 B2
8221395 Shelton et al. Jul 2012 B2
8226597 Jacobson et al. Jul 2012 B2
8231578 Fathallah et al. Jul 2012 B2
8234128 Martucci et al. Jul 2012 B2
8271106 Wehba et al. Sep 2012 B2
8287514 Miller et al. Oct 2012 B2
8291337 Gannin et al. Oct 2012 B2
8313308 Lawless et al. Nov 2012 B2
8317698 Lowery Nov 2012 B2
8317750 Ware et al. Nov 2012 B2
8317752 Cozmi et al. Nov 2012 B2
8318094 Bayandorian et al. Nov 2012 B1
8340792 Condurso et al. Dec 2012 B2
8347731 Genosar Jan 2013 B2
8359338 Butterfield et al. Jan 2013 B2
8361021 Wang et al. Jan 2013 B2
8378837 Wang et al. Feb 2013 B2
8388598 Steinkogler Mar 2013 B2
8398616 Budiman Mar 2013 B2
8403908 Jacobson et al. Mar 2013 B2
8409164 Fangrow Apr 2013 B2
8449524 Braig et al. May 2013 B2
8469942 Kow et al. Jun 2013 B2
8477307 Yufa et al. Jul 2013 B1
8494879 Davis et al. Jul 2013 B2
8504179 Blomquist Aug 2013 B2
8506552 Rebours Aug 2013 B2
8517990 Teel et al. Aug 2013 B2
8518021 Stewart et al. Aug 2013 B2
8522832 Lopez et al. Sep 2013 B2
8523797 Lowery et al. Sep 2013 B2
8539812 Stringham et al. Sep 2013 B2
8543416 Palmroos et al. Sep 2013 B2
8577692 Silkaitis et al. Nov 2013 B2
8622990 Estes et al. Jan 2014 B2
8630722 Condurso et al. Jan 2014 B2
8665214 Forutanpour et al. Mar 2014 B2
8666769 Butler et al. Mar 2014 B2
8700421 Feng et al. Apr 2014 B2
8706233 Su et al. Apr 2014 B2
8721584 Braithwaite et al. May 2014 B2
8728020 Caleffi et al. May 2014 B2
8758306 Lopez et al. Jun 2014 B2
8761906 Condurso et al. Jun 2014 B2
8768719 Wehba et al. Jul 2014 B2
8771251 Ruchti et al. Jul 2014 B2
8792981 Yudovsky et al. Jul 2014 B2
8821432 Unverdorben Sep 2014 B2
8823382 Rondoni et al. Sep 2014 B2
8857269 Johnson et al. Oct 2014 B2
8858185 Johnson et al. Oct 2014 B2
8905965 Mandro et al. Dec 2014 B2
8964185 Luo et al. Feb 2015 B1
9005150 Ware et al. Apr 2015 B2
9026370 Rubalcaba et al. May 2015 B2
9084855 Ware et al. Jul 2015 B2
9114217 Sur et al. Aug 2015 B2
9134735 Lowery et al. Sep 2015 B2
9134736 Lowery et al. Sep 2015 B2
9138526 Ware et al. Sep 2015 B2
9190010 Vik et al. Nov 2015 B2
9240002 Hume et al. Jan 2016 B2
9272089 Jacobson et al. Mar 2016 B2
9316216 Cook et al. Apr 2016 B1
9333291 Jacobson et al. May 2016 B2
9381296 Arrizza et al. Jul 2016 B2
9393362 Cozmi et al. Jul 2016 B2
9468718 Hung et al. Oct 2016 B2
9498583 Sur et al. Nov 2016 B2
9545475 Borges et al. Jan 2017 B2
9545476 Qi et al. Jan 2017 B2
9707341 Dumas, III et al. Jul 2017 B2
9764087 Peterfreund et al. Sep 2017 B2
9852265 Treacy et al. Dec 2017 B1
9883987 Lopez et al. Feb 2018 B2
9943269 Muhsin et al. Apr 2018 B2
9995611 Ruchti et al. Jun 2018 B2
10022498 Ruchti et al. Jul 2018 B2
10046112 Oruklu et al. Aug 2018 B2
10089055 Fryman Oct 2018 B1
10099009 Anderson et al. Oct 2018 B1
10166328 Oruklu et al. Jan 2019 B2
10342917 Shubinsky et al. Jul 2019 B2
10430761 Hume et al. Oct 2019 B2
10463788 Day Nov 2019 B2
10549248 Brown et al. Feb 2020 B2
10578474 Ruchti et al. Mar 2020 B2
10596316 Dumas, III et al. Mar 2020 B2
10635784 Rubalcaba, Jr. et al. Apr 2020 B2
10656894 Fryman May 2020 B2
10682102 Declerck Jun 2020 B2
10709885 Janders et al. Jul 2020 B2
10850024 Day et al. Dec 2020 B2
10874793 Oruklu et al. Dec 2020 B2
11004035 Hume et al. May 2021 B2
11007119 Lopez et al. May 2021 B2
D922432 Kataoka et al. Jun 2021 S
D923050 Kataoka et al. Jun 2021 S
11029911 Fryman Jun 2021 B2
D926201 Bryant et al. Jul 2021 S
D928813 Nurutdinov et al. Aug 2021 S
D928840 Amit et al. Aug 2021 S
11090431 Dumas, III et al. Aug 2021 B2
D931884 Bryant et al. Sep 2021 S
11135360 Jacobson et al. Oct 2021 B1
11246985 Gylland et al. Feb 2022 B2
11278671 Cavendish, Jr. et al. Mar 2022 B2
11298456 Shubinsky et al. Apr 2022 B2
11324888 Shubinsky et al. May 2022 B2
11344668 Sileika et al. May 2022 B2
11344673 Lindo et al. May 2022 B2
11376361 Ruchti et al. Jul 2022 B2
11378430 Ruchti et al. Jul 2022 B2
11395875 Rubalcaba, Jr. et al. Jul 2022 B2
11433177 Oruklu et al. Sep 2022 B2
11439570 Lopez et al. Sep 2022 B2
11596737 Dumas, III et al. Mar 2023 B2
11599854 Hume et al. Mar 2023 B2
11623042 Day Apr 2023 B2
11868161 Fryman Jan 2024 B2
11883361 Janssen Jan 2024 B2
11933650 Ruchti et al. Mar 2024 B2
11972395 Hume et al. Apr 2024 B2
20010007636 Butterfield Jul 2001 A1
20010014769 Bufe et al. Aug 2001 A1
20010015099 Blaine Aug 2001 A1
20010016056 Westphal et al. Aug 2001 A1
20010032099 Joao Oct 2001 A1
20010037060 Thompson et al. Nov 2001 A1
20010041869 Causey et al. Nov 2001 A1
20010044731 Coffman et al. Nov 2001 A1
20020003892 Iwanaga Jan 2002 A1
20020007116 Zatezalo et al. Jan 2002 A1
20020013545 Soltanpour et al. Jan 2002 A1
20020013551 Zaitsu et al. Jan 2002 A1
20020015018 Shimazu et al. Feb 2002 A1
20020018720 Carlisle et al. Feb 2002 A1
20020029776 Blomquist Mar 2002 A1
20020031838 Meinhart et al. Mar 2002 A1
20020032583 Joao Mar 2002 A1
20020038392 De La Huerga Mar 2002 A1
20020040208 Flaherty et al. Apr 2002 A1
20020044059 Reeder et al. Apr 2002 A1
20020045806 Baker, Jr. et al. Apr 2002 A1
20020082728 Mueller et al. Jun 2002 A1
20020083771 Khuri-Yakub et al. Jul 2002 A1
20020085952 Ellingboe et al. Jul 2002 A1
20020087115 Hartlaub Jul 2002 A1
20020093641 Ortyn et al. Jul 2002 A1
20020095486 Bahl Jul 2002 A1
20020099282 Knobbe et al. Jul 2002 A1
20020099334 Hanson et al. Jul 2002 A1
20020143580 Bristol et al. Oct 2002 A1
20020147389 Cavallaro et al. Oct 2002 A1
20020152239 Bautista-Lloyd et al. Oct 2002 A1
20020158919 Nacey Oct 2002 A1
20020168278 Jeon et al. Nov 2002 A1
20020173703 Lebel et al. Nov 2002 A1
20020183693 Peterson et al. Dec 2002 A1
20030009244 Engleson Jan 2003 A1
20030013959 Grunwald et al. Jan 2003 A1
20030018289 Ng et al. Jan 2003 A1
20030018308 Tsai Jan 2003 A1
20030025602 Medema et al. Feb 2003 A1
20030028082 Thompson Feb 2003 A1
20030030001 Cooper et al. Feb 2003 A1
20030045840 Burko Mar 2003 A1
20030050621 Lebel et al. Mar 2003 A1
20030060688 Ciarniello et al. Mar 2003 A1
20030060765 Campbell et al. Mar 2003 A1
20030065537 Evans Apr 2003 A1
20030065589 Giacchetti Apr 2003 A1
20030073954 Moberg et al. Apr 2003 A1
20030079746 Hickle May 2003 A1
20030083583 Kovtun et al. May 2003 A1
20030091442 Bush et al. May 2003 A1
20030104982 Wittmann et al. Jun 2003 A1
20030106553 Vanderveen Jun 2003 A1
20030125662 Bui Jul 2003 A1
20030130616 Steil Jul 2003 A1
20030135087 Hickle et al. Jul 2003 A1
20030136193 Fujimoto Jul 2003 A1
20030139701 White et al. Jul 2003 A1
20030140928 Bui et al. Jul 2003 A1
20030140929 Wilkes et al. Jul 2003 A1
20030141981 Bui et al. Jul 2003 A1
20030143746 Sage, Jr. Jul 2003 A1
20030144878 Wilkes et al. Jul 2003 A1
20030158508 DiGianfilippo Aug 2003 A1
20030159741 Sparks Aug 2003 A1
20030160683 Blomquist Aug 2003 A1
20030163789 Blomquist Aug 2003 A1
20030173408 Mosher, Jr. et al. Sep 2003 A1
20030186833 Huff et al. Oct 2003 A1
20030187338 Say et al. Oct 2003 A1
20030200116 Forrester Oct 2003 A1
20030204274 Ullestad et al. Oct 2003 A1
20030204416 Acharya Oct 2003 A1
20030212364 Mann et al. Nov 2003 A1
20030212379 Bylund et al. Nov 2003 A1
20030216682 Junker Nov 2003 A1
20030217962 Childers et al. Nov 2003 A1
20030233071 Gillespie, Jr. et al. Dec 2003 A1
20040030277 O'Mahony et al. Feb 2004 A1
20040047736 Nose et al. Mar 2004 A1
20040057226 Berthou et al. Mar 2004 A1
20040064342 Browne et al. Apr 2004 A1
20040073125 Lovett et al. Apr 2004 A1
20040073161 Tachibana Apr 2004 A1
20040077996 Jasperson et al. Apr 2004 A1
20040082908 Whitehurst Apr 2004 A1
20040082918 Evans et al. Apr 2004 A1
20040104271 Martucci et al. Jun 2004 A1
20040119753 Zencke Jun 2004 A1
20040120825 Bouton et al. Jun 2004 A1
20040128162 Schlotterbeck et al. Jul 2004 A1
20040128163 Goodman et al. Jul 2004 A1
20040133166 Moberg et al. Jul 2004 A1
20040145114 Ippolito et al. Jul 2004 A1
20040147034 Gore et al. Jul 2004 A1
20040149823 Aptekar Aug 2004 A1
20040152970 Hunter et al. Aug 2004 A1
20040158193 Bui et al. Aug 2004 A1
20040167464 Ireland et al. Aug 2004 A1
20040167465 Kohler Aug 2004 A1
20040167804 Simpson Aug 2004 A1
20040172222 Simpson et al. Sep 2004 A1
20040172283 Vanderveen Sep 2004 A1
20040172289 Kozic et al. Sep 2004 A1
20040172301 Mihai et al. Sep 2004 A1
20040172302 Martucci et al. Sep 2004 A1
20040176984 White et al. Sep 2004 A1
20040181314 Zaleski Sep 2004 A1
20040193025 Steil et al. Sep 2004 A1
20040193325 Bonderud Sep 2004 A1
20040193328 Butterfield et al. Sep 2004 A1
20040193453 Butterfield et al. Sep 2004 A1
20040204638 Diab et al. Oct 2004 A1
20040204673 Flaherty et al. Oct 2004 A1
20040220517 Starkweather et al. Nov 2004 A1
20040225252 Gillespie et al. Nov 2004 A1
20040225409 Duncan et al. Nov 2004 A1
20040232219 Fowler Nov 2004 A1
20040253123 Xie et al. Dec 2004 A1
20040254434 Goodnow et al. Dec 2004 A1
20040254513 Shang et al. Dec 2004 A1
20050021006 Tonnies Jan 2005 A1
20050021297 Hartlaub Jan 2005 A1
20050022274 Campbell et al. Jan 2005 A1
20050038680 McMahon Feb 2005 A1
20050055242 Bello et al. Mar 2005 A1
20050055244 Mullan et al. Mar 2005 A1
20050065465 Lebel et al. Mar 2005 A1
20050075544 Shapiro et al. Apr 2005 A1
20050096593 Pope et al. May 2005 A1
20050099624 Staehr May 2005 A1
20050107923 Vanderveen May 2005 A1
20050108057 Cohen et al. May 2005 A1
20050119597 O'Mahony et al. Jun 2005 A1
20050119914 Batch Jun 2005 A1
20050131739 Rabinowitz et al. Jun 2005 A1
20050137522 Aoki Jun 2005 A1
20050143864 Blomquist Jun 2005 A1
20050145010 Vanderveen et al. Jul 2005 A1
20050171503 Van Den Berghe et al. Aug 2005 A1
20050171815 Vanderveen Aug 2005 A1
20050177045 Degertekin et al. Aug 2005 A1
20050177096 Bollish et al. Aug 2005 A1
20050182306 Sloan Aug 2005 A1
20050182355 Bui Aug 2005 A1
20050182366 Vogt et al. Aug 2005 A1
20050187515 Varrichio et al. Aug 2005 A1
20050192529 Butterfield et al. Sep 2005 A1
20050192557 Brauker et al. Sep 2005 A1
20050197554 Polcha Sep 2005 A1
20050197621 Poulsen et al. Sep 2005 A1
20050209563 Hopping et al. Sep 2005 A1
20050209793 Yamada Sep 2005 A1
20050224083 Crass Oct 2005 A1
20050235732 Rush Oct 2005 A1
20050238506 Mescher et al. Oct 2005 A1
20050240305 Bogash et al. Oct 2005 A1
20050273059 Mernoe et al. Dec 2005 A1
20050277890 Stewart et al. Dec 2005 A1
20050279419 Tribble et al. Dec 2005 A1
20060002799 Schann et al. Jan 2006 A1
20060009727 O'Mahony et al. Jan 2006 A1
20060009734 Martin Jan 2006 A1
20060042633 Bishop et al. Mar 2006 A1
20060047270 Shelton Mar 2006 A1
20060053036 Coffman et al. Mar 2006 A1
20060064020 Burnes et al. Mar 2006 A1
20060064053 Bollish et al. Mar 2006 A1
20060079768 Small et al. Apr 2006 A1
20060079831 Gilbert Apr 2006 A1
20060100746 Leibner-Druska May 2006 A1
20060100907 Holland et al. May 2006 A1
20060106649 Eggers et al. May 2006 A1
20060116639 Russell Jun 2006 A1
20060117856 Orr et al. Jun 2006 A1
20060117867 Froehlich et al. Jun 2006 A1
20060122867 Eggers et al. Jun 2006 A1
20060135939 Brown Jun 2006 A1
20060135940 Joshi Jun 2006 A1
20060136095 Rob et al. Jun 2006 A1
20060136271 Eggers et al. Jun 2006 A1
20060140798 Kutsuzawa Jun 2006 A1
20060143051 Eggers et al. Jun 2006 A1
20060173260 Gaoni et al. Aug 2006 A1
20060173406 Hayes et al. Aug 2006 A1
20060180916 Wyland Aug 2006 A1
20060181695 Sage, Jr. Aug 2006 A1
20060187069 Duan Aug 2006 A1
20060190302 Eggers et al. Aug 2006 A1
20060195022 Trepagnier et al. Aug 2006 A1
20060200007 Brockway et al. Sep 2006 A1
20060200369 Batch et al. Sep 2006 A1
20060211404 Cromp et al. Sep 2006 A1
20060224140 Junker Oct 2006 A1
20060224141 Rush et al. Oct 2006 A1
20060224181 McEwen et al. Oct 2006 A1
20060226088 Robinson et al. Oct 2006 A1
20060226089 Robinson et al. Oct 2006 A1
20060226090 Robinson et al. Oct 2006 A1
20060229918 Fotsch et al. Oct 2006 A1
20060235353 Gelfand et al. Oct 2006 A1
20060255149 Retter et al. Nov 2006 A1
20060258985 Russell Nov 2006 A1
20060260416 Sage et al. Nov 2006 A1
20060264895 Flanders Nov 2006 A1
20060265246 Hoag Nov 2006 A1
20060266128 Clark et al. Nov 2006 A1
20060270971 Gelfand et al. Nov 2006 A1
20060271286 Rosenberg Nov 2006 A1
20060272421 Frinak et al. Dec 2006 A1
20060275142 Bouton et al. Dec 2006 A1
20070015972 Wang et al. Jan 2007 A1
20070036511 Lundquist et al. Feb 2007 A1
20070060796 Kim Mar 2007 A1
20070060869 Tolle et al. Mar 2007 A1
20070060871 Istoc Mar 2007 A1
20070060872 Hall et al. Mar 2007 A1
20070060874 Nesbitt et al. Mar 2007 A1
20070062250 Krulevitch et al. Mar 2007 A1
20070065363 Dalal et al. Mar 2007 A1
20070078314 Grounsell Apr 2007 A1
20070083152 Williams, Jr. et al. Apr 2007 A1
20070084286 Ajay et al. Apr 2007 A1
20070084288 Thomas et al. Apr 2007 A1
20070088271 Richards Apr 2007 A1
20070088333 Levin et al. Apr 2007 A1
20070093753 Krulevitcvh et al. Apr 2007 A1
20070094045 Cobbs et al. Apr 2007 A1
20070094046 Cobbs et al. Apr 2007 A1
20070100222 Mastrototaro et al. May 2007 A1
20070100665 Brown May 2007 A1
20070112298 Mueller et al. May 2007 A1
20070118405 Campbell et al. May 2007 A1
20070129618 Goldberger et al. Jun 2007 A1
20070142822 Remde Jun 2007 A1
20070156452 Batch Jul 2007 A1
20070156456 McGillin et al. Jul 2007 A1
20070179436 Braig et al. Aug 2007 A1
20070180916 Tian et al. Aug 2007 A1
20070191770 Moberg et al. Aug 2007 A1
20070191817 Martin Aug 2007 A1
20070197963 Griffiths et al. Aug 2007 A1
20070214003 Holland et al. Sep 2007 A1
20070215545 Bissler et al. Sep 2007 A1
20070233035 Wehba et al. Oct 2007 A1
20070233049 Wehba et al. Oct 2007 A1
20070240497 Robinson et al. Oct 2007 A1
20070250339 Mallett et al. Oct 2007 A1
20070255250 Moberg et al. Nov 2007 A1
20070257788 Carlson Nov 2007 A1
20070267945 Sudol Nov 2007 A1
20070270747 Remde Nov 2007 A1
20070274843 Vanderveen et al. Nov 2007 A1
20070289384 Sakai et al. Dec 2007 A1
20080009684 Corsetti et al. Jan 2008 A1
20080028868 Konzelmann et al. Feb 2008 A1
20080033361 Evans et al. Feb 2008 A1
20080039777 Katz et al. Feb 2008 A1
20080048211 Khuri-Yakub et al. Feb 2008 A1
20080058773 John Mar 2008 A1
20080060448 Wiest et al. Mar 2008 A1
20080065420 Tirinato et al. Mar 2008 A1
20080071210 Moubayed et al. Mar 2008 A1
20080071496 Glascock Mar 2008 A1
20080071580 Marcus et al. Mar 2008 A1
20080077116 Dailey et al. Mar 2008 A1
20080086087 Spohn et al. Apr 2008 A1
20080091466 Butler et al. Apr 2008 A1
20080097288 Levin et al. Apr 2008 A1
20080097289 Steil et al. Apr 2008 A1
20080097317 Alholm et al. Apr 2008 A1
20080098798 Riley et al. May 2008 A1
20080119822 Knauper May 2008 A1
20080125701 Moberg et al. May 2008 A1
20080139907 Rao et al. Jun 2008 A1
20080145249 Smisson Jun 2008 A1
20080169044 Osborne et al. Jul 2008 A1
20080172030 Blomquist et al. Jul 2008 A1
20080177254 Shelton et al. Jul 2008 A1
20080184784 Dam Aug 2008 A1
20080188789 Galavotti et al. Aug 2008 A1
20080188796 Steil et al. Aug 2008 A1
20080208484 Butterfield et al. Aug 2008 A1
20080214919 Harmon et al. Sep 2008 A1
20080221521 Getz et al. Sep 2008 A1
20080221522 Moberg et al. Sep 2008 A1
20080262469 Bristol et al. Oct 2008 A1
20080269663 Arnold et al. Oct 2008 A1
20080269714 Mastrototaro et al. Oct 2008 A1
20080269723 Mastrototaro et al. Oct 2008 A1
20080275384 Mastrototaro et al. Nov 2008 A1
20080300572 Rankers et al. Dec 2008 A1
20090001908 Shubinsky et al. Jan 2009 A1
20090005703 Fasciano Jan 2009 A1
20090006061 Thukral et al. Jan 2009 A1
20090006129 Thukral Jan 2009 A1
20090006133 Weinert Jan 2009 A1
20090015824 Shubinsky et al. Jan 2009 A1
20090043171 Rule Feb 2009 A1
20090054743 Stewart Feb 2009 A1
20090054754 McMahon et al. Feb 2009 A1
20090069743 Krishnamoorthy et al. Mar 2009 A1
20090077248 Castellucci et al. Mar 2009 A1
20090082676 Bennison Mar 2009 A1
20090088731 Campbell et al. Apr 2009 A1
20090097029 Tokhtuev et al. Apr 2009 A1
20090099866 Newman Apr 2009 A1
20090105636 Hayter et al. Apr 2009 A1
20090112155 Zhao Apr 2009 A1
20090114037 Smith May 2009 A1
20090119330 Sampath et al. May 2009 A1
20090124963 Hogard et al. May 2009 A1
20090124964 Leach et al. May 2009 A1
20090126825 Eliuk et al. May 2009 A1
20090131861 Braig et al. May 2009 A1
20090135196 Holland et al. May 2009 A1
20090143726 Bouton et al. Jun 2009 A1
20090144025 Bouton et al. Jun 2009 A1
20090144026 Bouton et al. Jun 2009 A1
20090149743 Barron et al. Jun 2009 A1
20090156922 Goldberger et al. Jun 2009 A1
20090156975 Robinson et al. Jun 2009 A1
20090171289 Davis et al. Jul 2009 A1
20090177146 Nesbitt et al. Jul 2009 A1
20090177180 Rubalcaba et al. Jul 2009 A1
20090177188 Steinkogler Jul 2009 A1
20090177248 Roberts Jul 2009 A1
20090177769 Roberts Jul 2009 A1
20090177992 Rubalcaba et al. Jul 2009 A1
20090178485 Thomas et al. Jul 2009 A1
20090183147 Davis et al. Jul 2009 A1
20090192367 Braig et al. Jul 2009 A1
20090198347 Kirzinger Aug 2009 A1
20090205426 Balschat et al. Aug 2009 A1
20090209938 Aalto-Setala Aug 2009 A1
20090209945 Lobl et al. Aug 2009 A1
20090212966 Panduro Aug 2009 A1
20090221890 Saffer et al. Sep 2009 A1
20090223294 Thomas et al. Sep 2009 A1
20090227939 Memoe et al. Sep 2009 A1
20090264720 Torjman et al. Oct 2009 A1
20090270810 DeBelser Oct 2009 A1
20090270833 DeBelser Oct 2009 A1
20100022988 Wochner Jan 2010 A1
20100280430 Caleffi et al. Jan 2010 A1
20100036310 Hillman Feb 2010 A1
20100056992 Hayter Mar 2010 A1
20100057042 Hayter Mar 2010 A1
20100069892 Steinbach et al. Mar 2010 A1
20100077866 Graboi et al. Apr 2010 A1
20100079760 Bernacki Apr 2010 A1
20100094251 Estes et al. Apr 2010 A1
20100106082 Zhou Apr 2010 A1
20100114027 Jacobson et al. May 2010 A1
20100121170 Rule May 2010 A1
20100121415 Skelton et al. May 2010 A1
20100130933 Holland et al. May 2010 A1
20100131434 Magent et al. May 2010 A1
20100141460 Tokhtuev et al. Jun 2010 A1
20100147081 Thomas et al. Jun 2010 A1
20100152554 Steine et al. Jun 2010 A1
20100160854 Gauthier Jun 2010 A1
20100168535 Robinson et al. Jul 2010 A1
20100177375 Seyfried Jul 2010 A1
20100185142 Kamen et al. Jul 2010 A1
20100185182 Alme et al. Jul 2010 A1
20100198034 Thomas et al. Aug 2010 A1
20100198182 Lanigan et al. Aug 2010 A1
20100198183 Lanigan et al. Aug 2010 A1
20100211002 Davis Aug 2010 A1
20100212407 Stringham et al. Aug 2010 A1
20100212675 Walling et al. Aug 2010 A1
20100217154 Deshmukh et al. Aug 2010 A1
20100217621 Schoenberg Aug 2010 A1
20100271218 Hoag et al. Oct 2010 A1
20100271479 Heydlauf Oct 2010 A1
20100273738 Valcke et al. Oct 2010 A1
20100292634 Kircher Nov 2010 A1
20100295686 Sloan et al. Nov 2010 A1
20100298765 Budiman et al. Nov 2010 A1
20100312039 Quirico et al. Dec 2010 A1
20100317093 Turewicz et al. Dec 2010 A1
20100317952 Budiman et al. Dec 2010 A1
20100318025 John Dec 2010 A1
20110000560 Miller et al. Jan 2011 A1
20110001605 Kiani et al. Jan 2011 A1
20110004186 Butterfield Jan 2011 A1
20110009797 Kelly et al. Jan 2011 A1
20110028885 Eggers et al. Feb 2011 A1
20110040247 Mandro et al. Feb 2011 A1
20110046558 Gravesen et al. Feb 2011 A1
20110054311 Williams et al. Mar 2011 A1
20110062703 Lopez et al. Mar 2011 A1
20110064612 Franzoni et al. Mar 2011 A1
20110071464 Palerm Mar 2011 A1
20110071844 Cannon et al. Mar 2011 A1
20110072379 Gannon Mar 2011 A1
20110077480 Bloom et al. Mar 2011 A1
20110078608 Gannon et al. Mar 2011 A1
20110099313 Bolanowski Apr 2011 A1
20110105983 Kelly et al. May 2011 A1
20110106561 Eaton, Jr. et al. May 2011 A1
20110107251 Guaitoli et al. May 2011 A1
20110137241 DelCastillo et al. Jun 2011 A1
20110144595 Cheng Jun 2011 A1
20110152770 Diperna et al. Jun 2011 A1
20110160649 Pan Jun 2011 A1
20110162647 Huby et al. Jul 2011 A1
20110172918 Tome Jul 2011 A1
20110175728 Baker, Jr. Jul 2011 A1
20110190598 Shusterman Aug 2011 A1
20110190694 Lanier et al. Aug 2011 A1
20110218514 Rebours Sep 2011 A1
20110238032 McTaggart Sep 2011 A1
20110264006 Ali et al. Oct 2011 A1
20110264043 Kotnick et al. Oct 2011 A1
20110282321 Steil et al. Nov 2011 A1
20110313390 Roy et al. Dec 2011 A1
20110319728 Petisce et al. Dec 2011 A1
20110320049 Chossat et al. Dec 2011 A1
20120016215 Condurso et al. Jan 2012 A1
20120025995 Moberg et al. Feb 2012 A1
20120059234 Barrett et al. Mar 2012 A1
20120068001 Pushkarsky et al. Mar 2012 A1
20120083760 Ledford et al. Apr 2012 A1
20120089411 Srnka et al. Apr 2012 A1
20120095433 Hungerford et al. Apr 2012 A1
20120123322 Scarpaci et al. May 2012 A1
20120143116 Ware et al. Jun 2012 A1
20120180790 Montgomery Jul 2012 A1
20120185267 Kamen et al. Jul 2012 A1
20120191059 Cummings et al. Jul 2012 A1
20120194341 Peichel et al. Aug 2012 A1
20120203177 Lanier Aug 2012 A1
20120222774 Husnu et al. Sep 2012 A1
20120226350 Rudser et al. Sep 2012 A1
20120245525 Pope et al. Sep 2012 A1
20120259278 Hayes et al. Oct 2012 A1
20120310204 Krogh et al. Dec 2012 A1
20120323212 Murphy Dec 2012 A1
20130006666 Schneider Jan 2013 A1
20130009551 Knapp Jan 2013 A1
20130012880 Blomquist Jan 2013 A1
20130012917 Miller et al. Jan 2013 A1
20130032634 McKirdy Feb 2013 A1
20130041342 Bernini et al. Feb 2013 A1
20130044111 VanGilder et al. Feb 2013 A1
20130110538 Butterfield et al. May 2013 A1
20130150766 Olde et al. Jun 2013 A1
20130150821 Bollish et al. Jun 2013 A1
20130177455 Kamen Jul 2013 A1
20130184676 Kamen et al. Jul 2013 A1
20130197930 Garibaldi et al. Aug 2013 A1
20130201482 Munro Aug 2013 A1
20130218080 Peterfreund et al. Aug 2013 A1
20130116649 Kouyoumjian et al. Sep 2013 A1
20130253430 Kouyoumjian et al. Sep 2013 A1
20130253946 Broselow Sep 2013 A1
20130274576 Amirouche et al. Oct 2013 A1
20130281965 Kamen et al. Oct 2013 A1
20130291116 Homer Oct 2013 A1
20130296823 Melker et al. Nov 2013 A1
20130296984 Burnett et al. Nov 2013 A1
20130318158 Teng et al. Nov 2013 A1
20130322201 Hitchcock et al. Dec 2013 A1
20130345658 Browne et al. Dec 2013 A1
20130345666 Panduro et al. Dec 2013 A1
20140039446 Day Feb 2014 A1
20140067425 Dudar et al. Mar 2014 A1
20140145915 Ribble et al. May 2014 A1
20140180711 Kamen et al. Jun 2014 A1
20140224829 Capone et al. Aug 2014 A1
20140267563 Baca et al. Sep 2014 A1
20140303754 Nixon et al. Oct 2014 A1
20140358077 Oruklu et al. Dec 2014 A1
20150025453 Ledford et al. Jan 2015 A1
20150033073 Yang et al. Jan 2015 A1
20150051458 Chen Feb 2015 A1
20150065988 Holderle et al. Mar 2015 A1
20150114515 Phallen Apr 2015 A1
20150141921 Stewart et al. May 2015 A1
20150168958 Downie et al. Jun 2015 A1
20150224252 Borges et al. Aug 2015 A1
20150246175 Shubinsky et al. Sep 2015 A1
20150265765 Yavorsky et al. Sep 2015 A1
20150338340 Jiang et al. Nov 2015 A1
20150343141 Lindo et al. Dec 2015 A1
20150371004 Jones Dec 2015 A1
20160042264 Borges et al. Feb 2016 A1
20160051750 Tsoukalis Feb 2016 A1
20160103960 Hume et al. Apr 2016 A1
20160110088 Vik et al. Apr 2016 A1
20160144101 Pananen May 2016 A1
20160151560 Toro et al. Jun 2016 A1
20160151562 Magers et al. Jun 2016 A1
20160151601 Cardelius et al. Jun 2016 A1
20160158437 Biasi et al. Jun 2016 A1
20160175517 Sileika et al. Jun 2016 A1
20160193604 McFarland et al. Jul 2016 A1
20160253460 Kanada Sep 2016 A1
20160339167 Ledford et al. Nov 2016 A1
20170043089 Handler Feb 2017 A1
20170132867 Berg et al. May 2017 A1
20170354941 Brown et al. Dec 2017 A1
20180018440 Sugawara Jan 2018 A1
20180028749 Dumas, III et al. Feb 2018 A1
20180300994 Nelson et al. Oct 2018 A1
20190091401 Ruchti et al. Mar 2019 A1
20190101425 Ruchti et al. Apr 2019 A1
20190117890 Oruklu et al. Apr 2019 A1
20190196770 Fryman Jun 2019 A1
20190262535 Shubinsky et al. Aug 2019 A1
20190282757 Gylland et al. Sep 2019 A1
20190351131 Butterfield et al. Nov 2019 A1
20200069864 Shubinsky et al. Mar 2020 A1
20200113784 Lopez et al. Apr 2020 A1
20200238007 Day Jul 2020 A1
20200271499 Ruchti et al. Aug 2020 A1
20200282137 Dumas, III et al. Sep 2020 A1
20200324044 Gylland et al. Oct 2020 A1
20200330689 Nemoto et al. Oct 2020 A1
20200357500 Rubalcaba, Jr. et al. Nov 2020 A1
20210162115 Surine Jun 2021 A1
20210170101 Cavendish, Jr. et al. Jun 2021 A1
20210260283 Oruklu et al. Aug 2021 A1
20210304864 Kamen et al. Sep 2021 A1
20210397396 Fryman Dec 2021 A1
20220142865 Janssen May 2022 A1
20220176037 Jacobson et al. Jun 2022 A1
20220184302 Cavendish, Jr. et al. Jun 2022 A1
20220296806 Shubinsky et al. Sep 2022 A1
20220305200 Gylland et al. Sep 2022 A1
20220331518 Shubinsky et al. Oct 2022 A1
20220362463 Lindo et al. Nov 2022 A1
20230010290 Oruklu et al. Jan 2023 A1
20230010638 Rubalcaba, Jr. et al. Jan 2023 A1
20230017117 Sileika et al. Jan 2023 A1
20230058662 Ruchti et al. Feb 2023 A1
20230058894 Ruchti et al. Feb 2023 A1
20230112979 Xavier Apr 2023 A1
20230115595 Cousineau et al. Apr 2023 A1
20230181419 Fister Jun 2023 A1
20230270938 Dumas, III et al. Aug 2023 A1
20230285669 Day Sep 2023 A1
20230310735 Cousineau Oct 2023 A1
20230325772 Hume et al. Oct 2023 A1
Foreign Referenced Citations (193)
Number Date Country
2013216679 Sep 2013 AU
PI0704229-9 Nov 2009 BR
2 113 473 Mar 1993 CA
2 551 817 Jul 2005 CA
2 554 407 Aug 2005 CA
107106042 Aug 2017 CN
31 12 762 Jan 1983 DE
34 35 647 Jul 1985 DE
35 30 747 Mar 1987 DE
37 20 664 Jan 1989 DE
38 27 444 Feb 1990 DE
197 34 002 Sep 1998 DE
199 01 078 Feb 2000 DE
198 40 965 Mar 2000 DE
198 44 252 Mar 2000 DE
199 32 147 Jan 2001 DE
102 49 238 May 2004 DE
103 52 456 Jul 2005 DE
0 282 323 Sep 1988 EP
0 291 727 Nov 1988 EP
0 319 272 Jun 1989 EP
0 319 275 Jun 1989 EP
0 335 385 Oct 1989 EP
0 337 092 Oct 1989 EP
0 341 582 Nov 1989 EP
0 370 162 May 1990 EP
0 387 724 Sep 1990 EP
0 429 866 Jun 1991 EP
0 441 323 Aug 1991 EP
0 453 211 Oct 1991 EP
0 462 405 Dec 1991 EP
0 501 234 Sep 1992 EP
0 516 130 Dec 1992 EP
0 519 765 Dec 1992 EP
0 643 301 Mar 1995 EP
0 683 465 Nov 1995 EP
0 431 310 Jan 1996 EP
0 814 864 Jan 1998 EP
0 589 439 Aug 1998 EP
0 880 936 Dec 1998 EP
0 954 090 Nov 1999 EP
0 960 627 Dec 1999 EP
1 174 817 Jan 2002 EP
1 177 802 Feb 2002 EP
1 197 178 Apr 2002 EP
1 500 025 Apr 2003 EP
1 813 188 Aug 2007 EP
1 490 131 Dec 2007 EP
2 062 527 May 2009 EP
2 228 004 Sep 2010 EP
2 243 506 Oct 2010 EP
2 381 260 Oct 2011 EP
254513 Oct 1981 ES
2 717 919 Sep 1995 FR
2 121 971 Jan 1984 GB
2 303 706 Feb 1997 GB
2 312 022 Oct 1997 GB
2 312 046 Oct 1997 GB
01-301118 Dec 1989 JP
01-308568 Dec 1989 JP
04-231966 Aug 1992 JP
07-502678 Mar 1995 JP
07-289638 Nov 1995 JP
11-128344 May 1999 JP
2000-111374 Apr 2000 JP
2000-510575 Aug 2000 JP
2000-515716 Nov 2000 JP
2001-356034 Dec 2001 JP
2002-506514 Feb 2002 JP
2002-131105 May 2002 JP
2003-038642 Feb 2003 JP
2003-050144 Feb 2003 JP
2005-021463 Jan 2005 JP
2005-524081 Mar 2005 JP
2006-517423 Jul 2006 JP
2007-071695 Mar 2007 JP
2007-518471 Jul 2007 JP
2007-520270 Jul 2007 JP
2007-275106 Oct 2007 JP
2008-249400 Oct 2008 JP
4322661 Jun 2009 JP
2009-148592 Jul 2009 JP
2010-063767 Mar 2010 JP
5716879 Mar 2015 JP
WO 84000690 Mar 1984 WO
WO 84000894 Mar 1984 WO
WO 90007942 Jul 1990 WO
WO 91000113 Jan 1991 WO
WO 91016087 Oct 1991 WO
WO 91016416 Oct 1991 WO
WO 93004284 Mar 1993 WO
WO 95016200 Jun 1995 WO
WO 95031233 Nov 1995 WO
WO 96008755 Mar 1996 WO
WO 96025186 Aug 1996 WO
WO 96028209 Sep 1996 WO
WO 96041156 Dec 1996 WO
WO 97010013 Mar 1997 WO
WO 97030333 Aug 1997 WO
WO 98004304 Feb 1998 WO
WO 98012670 Mar 1998 WO
WO 98014234 Apr 1998 WO
WO 98019263 May 1998 WO
WO 98044320 Oct 1998 WO
WO 98056441 Dec 1998 WO
WO 99010029 Mar 1999 WO
WO 99015216 Apr 1999 WO
WO 99051003 Oct 1999 WO
WO 99052575 Oct 1999 WO
WO 00013580 Mar 2000 WO
WO 00013726 Mar 2000 WO
WO 00041621 Jul 2000 WO
WO 01014974 Mar 2001 WO
WO 01033484 May 2001 WO
WO 02005702 Jan 2002 WO
WO 02009795 Feb 2002 WO
WO 02027276 Apr 2002 WO
WO 02066101 Aug 2002 WO
WO 02087664 Nov 2002 WO
WO 03006091 Jan 2003 WO
WO 03053498 Jul 2003 WO
WO 03093780 Nov 2003 WO
WO 2004035115 Apr 2004 WO
WO 2004060455 Jul 2004 WO
WO 2004061745 Jul 2004 WO
WO 2004070556 Aug 2004 WO
WO 2004070994 Aug 2004 WO
WO 2004112579 Dec 2004 WO
WO 2005018716 Mar 2005 WO
WO 2005030489 Apr 2005 WO
WO 2005036447 Apr 2005 WO
WO 2005050526 Jun 2005 WO
WO 2005057175 Jun 2005 WO
WO 2005065146 Jul 2005 WO
WO 2005065749 Jul 2005 WO
WO 2005082450 Sep 2005 WO
WO 2005118015 Dec 2005 WO
WO 2006016122 Feb 2006 WO
WO 2006022906 Mar 2006 WO
WO 2006026270 Mar 2006 WO
WO 2007000426 Jan 2007 WO
WO 2007033025 Mar 2007 WO
WO 2007035567 Mar 2007 WO
WO 2007087443 Aug 2007 WO
WO 2008004560 Jan 2008 WO
WO 2008019016 Feb 2008 WO
WO 2008053193 May 2008 WO
WO 2008059492 May 2008 WO
WO 2008063429 May 2008 WO
WO 2008067245 Jun 2008 WO
WO 2008088490 Jul 2008 WO
WO 2008134146 Nov 2008 WO
WO 2009016504 Feb 2009 WO
WO 2009023406 Feb 2009 WO
WO 2009023407 Feb 2009 WO
WO 2009023634 Feb 2009 WO
WO 2009039203 Mar 2009 WO
WO 2009039214 Mar 2009 WO
WO 2009049252 Apr 2009 WO
WO 2009127683 Oct 2009 WO
WO 2009141504 Nov 2009 WO
WO 2010017279 Feb 2010 WO
WO 2010075371 Jul 2010 WO
WO 2010099313 Sep 2010 WO
WO 2010114929 Oct 2010 WO
WO 2010119409 Oct 2010 WO
WO 2010124127 Oct 2010 WO
WO 2010135646 Nov 2010 WO
WO 2010135654 Nov 2010 WO
WO 2010135670 Nov 2010 WO
WO 2010135686 Nov 2010 WO
WO 2010148205 Dec 2010 WO
WO 2011017778 Feb 2011 WO
WO 2011080188 Jul 2011 WO
WO 2011109774 Sep 2011 WO
WO 2012042763 Apr 2012 WO
WO 2012082599 Jun 2012 WO
WO 2012108910 Aug 2012 WO
WO 2012167090 Dec 2012 WO
WO 2013036854 Mar 2013 WO
WO 2013096769 Jun 2013 WO
WO 2015134478 Sep 2015 WO
WO 2017051271 Mar 2017 WO
WO 2017144366 Aug 2017 WO
WO 2017197024 Nov 2017 WO
WO 2019092680 May 2019 WO
WO 2020214717 Oct 2020 WO
WO 2022020184 Jan 2022 WO
WO 2022125471 Jun 2022 WO
WO 2023064662 Apr 2023 WO
WO 2023108030 Jun 2023 WO
WO 2023192791 Oct 2023 WO
WO 2023244922 Dec 2023 WO
Non-Patent Literature Citations (65)
Entry
Abbott Laboratories, “LifeCare® 5000, Plum®: Concurrent Flow Infusion System with DataPort™”, System Operating Manual, Version 1.6, Jul. 1998, pp. 76.
Daimiwal et al., “Wireless Transfusion Supervision and Analysis Using Embedded System”, IEEE, 2010 International Conference ICBBT, China, Apr. 2010, pp. 56-60.
Alaedeen et al., “Total Parenteral Nutrition-Associated Hyperglycemia Correlates with Prolonged Mechanical Ventilation and Hospital Stay in Septic Infants”, Journal of Pediatric Surgery, Jan. 2006, vol. 41, No. 1, pp. 239-244.
ALARIS® Medical Systems, “Signature Edition® GOLD—Single & Dual Channel Infusion System”, San Diego, CA, USA, date unknown, but believed to be at least as early as Nov. 29, 2008, pp. 2-88 & 2-91.
Allegro, “3955—Full-Bridge PWM Microstepping Motor Drive”, Datasheet, 1997, pp. 16.
Aragon, Daleen RN, Ph.D., CCRN, “Evaluation of Nursing Work Effort and Perceptions About Blood Glucose Testing in Tight Glycemic Control”, American Journal of Critical Care, Jul. 2006, vol. 15, No. 4, pp. 370-377.
Baxter, “Baxter Receives 510(k) Clearance for Next-Generation SIGMA Spectrum Infusion Pump with Master Drug Library” Press Release, May 8, 2014, pp. 2. http://web.archive.org/web/20160403140025/http://www.baxter.com/news-media/newsroom/press-releases/2014/05_08_14_sigma.page.
Bequette, Ph.D., “A Critical Assessment of Algorithms and Challenges in the Development of a Closed-Loop Artificial Pancreas”, Diabetes Technology & Therapeutics, Feb. 28, 2005, vol. 7, No. 1, pp. 28-47.
Bequette, B. Wayne, Ph.D., “Analysis of Algorithms for Intensive Care Unit Blood Glucose Control”, Journal of Diabetes Science and Technology, Nov. 2007, vol. 1, No. 6, pp. 813-824.
Binder et al., “Insulin Infusion with Parenteral Nutrition in Extremely Low Birth Weight Infants with Hyperglycemia”, Journal of Pediatrics, Feb. 1989, vol. 114, No. 2, pp. 273-280.
Bode et al., “Intravenous Insulin Infusion Therapy: Indications, Methods, and Transition to Subcutaneous Insulin Therapy”, Endocrine Practice, Mar./Apr. 2004, vol. 10, Supplement 2, pp. 71-80.
Buhrdorf et al., “Capacitive Micromachined Ultrasonic Transducers and their Application”, Proceedings of the IEEE Ultrasonics Symposium, Feb. 2001, vol. 2, pp. 933-940.
Cannon, MD et al., “Automated Heparin-Delivery System to Control Activated Partial Thromboplastin Time”, Circulation, Feb. 16, 1999, vol. 99, pp. 751-756.
“CareAware® Infusion Management”, Cerner Store, as printed May 12, 2011, pp. 3, https://store.cerner.com/items/7.
Chen et al., “Enabling Location-Based Services on Wireless LANs”, The 11th IEEE International Conference on Networks, ICON 2003, Sep. 28-Oct. 1, 2003, pp. 567-572.
Cheung et al., “Hyperglycemia is Associated with Adverse Outcomes in Patients Receiving Total Parenteral Nutrition”, Diabetes Care, Oct. 2005, vol. 28, No. 10, pp. 2367-2371.
Coley et al., “Performance of Three Portable Infusion-Pump Devices Set to Deliver 2 mL/hr”, American Journal of Health-System Pharmacy, Jun. 1, 1997, vol. 54, No. 11, pp. 1277-1280.
“Continually vs Continuously”, https://web.archive.org/web/20090813092423/http://www.diffen.com/difference/Continually_vs_Continuously, as accessed Aug. 13, 2009 in 4 pages.
“CritiCore® Monitor: Critical Fluid Output and Core Bladder Temperature Monitor”, BARD Urological Catheter Systems, Advertisement, 2005, pp. 2.
Davidson et al., “A Computer-Directed Intravenous Insulin System Shown to be Safe, Simple, and Effective in 120,618 h of Operation”, Diabetes Care, Oct. 2005, vol. 28, No. 10, pp. 2418-2423.
“Decision of the Administrative Council of Oct. 16, 2013 Amending Rule 135 and 164 of the Implementing Regulations to the European Patent Convention (CA/D 17/13)”, Official Journal EPO Nov. 2013, Nov. 2013, pp. 503-506. http://archive.epo.org/epo/pubs/oj013/11_13/11_5033.pdf.
“Decision of the Administrative Council of Oct. 27, 2009 Amending the Implementing Regulations to the European Patent Convention (CA/D 20/09)”, Official Journal EPO Dec. 2009, Dec. 2009, pp. 582-584. http://archive.epo.org/epo/pubs/oj009/12_09/12_5829.pdf.
Diabetes Close Up, Close Concerns AACE Inpatient Management Conference Report, Consensus Development Conference on Inpatient Diabetes and Metabolic Control, Washington, D.C., Dec. 14-16, 2003, pp. 1-32.
“Differential Pressure Transmitter, Series PD-39 X”, SensorsOne Ltd., Advertisement, Dec. 2005, pp. 2.
Dunster et al., “Flow Continuity of Infusion Systems at Low Flow Rates”, Anaesthesia and Intensive Care, Oct. 1995, vol. 23, No. 5, pp. 5.
Fogt et al., Development and Evaluation of a Glucose Analyzer for a Glucose-Controlled Insulin Infusion System (Biostator®), Clinical Chemistry, 1978, vol. 24, No. 8, pp. 1366-1372.
“Froth”, http://www.merriam-webster.com/dictionary/froth, as accessed May 13, 2015 in 1 page.
Goldberg et al., “Clinical Results of an Updated Insulin Infusion Protocol in Critically III Patients”, Diabetes Spectrum, 2005, vol. 18, No. 3, pp. 188-191.
Halpern et al., “Changes in Critical Care Beds and Occupancy in the United States 1985-2000: Differences Attributable to Hospital Size”, Critical Care Medical, Aug. 2006, vol. 34, No. 8, pp. 2105-2112.
Hospira, “Plum A+™ Infusion System” as archived Dec. 1, 2012, pp. 2. www.hospira.com/products_and_services/infusion_pumps/plum/index.
Hospira, “Plum XL™ Series Infusion System” Technical Service Manual, Feb. 2005, Lake Forest, Illinois, USA, pp. i-vii, 5-14, 8-3.
Ilfeld et al., “Delivery Rate Accuracy of Portable, Bolus-Capable Infusion Pumps Used for Patient-Controlled Continuous Regional Analgesia”, Regional Anesthesia and Pain Medicine, Jan.-Feb. 2003, vol. 28, No. 1, pp. 17-23.
Ilfeld et al., “Portable Infusion Pumps Used for Continuous Regional Analgesia: Delivery Rate Accuracy and Consistency”, Regional Anesthesia and Pain Medicine, Sep.-Oct. 2003, vol. 28, No. 5, pp. 424-432.
JMS Co., Ltd., “Infusion Pump: OT-701”, Tokyo, Japan, 2002, pp. 4.
Kim, M.D., et al., “Hyperglycemia Control of the Nil Per Os Patient in the Intensive Care Unit: Introduction of a Simple Subcutaneous Insulin Algorithm”, Nov. 2012, Journal of Diabetes Science and Technology, vol. 6, No. 6, pp. 1413-1419.
Kutcher et al., “The Effect of Lighting Conditions on Caries Interpretation with a Laptop Computer in a Clinical Setting”, Elsevier, Oct. 2006, vol. 102, No. 4, pp. 537-543.
Lamsdale et al., “A Usability Evaluation of an Infusion Pump by Nurses Using a Patient Simulator”, Proceedings of the Human Factors and Ergonomics Society 49th Annual Meeting, Sep. 2005, pp. 1024-1028.
Logan et al., “Fabricating Capacitive Micromachined Ultrasonic Transducers with a Novel Silicon-Nitride-Based Wafer Bonding Process”, IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, May 2009, vol. 56, No. 5, pp. 1074-1084.
Magaji et al., “Inpatient Management of Hyperglycemia and Diabetes”, Clinical Diabetes, 2011, vol. 29, No. 1, pp. 3-9.
Mauseth et al., “Proposed Clinical Application for Tuning Fuzzy Logic Controller of Artificial Pancreas Utilizing a Personalization Factor”, Journal of Diabetes Science and Technology, Jul. 2010, vol. 4, No. 4, pp. 913-922.
Maynard et al., “Subcutaneous Insulin Order Sets and Protocols: Effective Design and Implementation Strategies”, Journal of Hospital Medicine, Sep./Oct. 2008, vol. 3, Issue 5, Supplement 5, pp. S29-S41.
Merry et al., “A New, Safety-Oriented, Integrated Drug Administration and Automated Anesthesia Record System”, Anesthesia & Analgesia, Aug. 2001, vol. 93, No. 2 pp. 385-390.
Microchip Technology Inc., “MTA11200B; TrueGauge™ Intelligent Battery Management I.C.”, https://www.elektronik.ropla.eu/pdf/stock/mcp/mta11200b.pdf, 1995, pp. 44.
Moghissi, Etie, MD, FACP, FACE, “Hyperglycemia in Hospitalized Patients”, A Supplement to ACP Hospitalist, Jun. 15, 2008, pp. 32.
Nuckols et al., “Programmable Infusion Pumps in ICUs: An Analysis of Corresponding Adverse Drug Events”, Journal of General Internal Medicine, 2007, vol. 23, Supp. 1, pp. 41-45.
Pretty et al., “Hypoglycemia Detection in Critical Care Using Continuous Glucose Monitors: An in Silico Proof of Concept Analysis”, Journal of Diabetes Science and Technology, Jan. 2010, vol. 4, No. 1, pp. 15-24.
Saager et al., “Computer-Guided Versus Standard Protocol for Insulin Administration in Diabetic Patients Undergoing Cardiac Surgery”, Annual Meeting of the American Society of Critical Care Anesthesiologists, Oct. 13, 2006.
Sebald et al., “Numerical Analysis of a Comprehensive in Silico Subcutaneous Insulin Absorption Compartmental Model”, 31st Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Sep. 2-6, 2009, pp. 3901-3904.
SGS-Thomson Microelectronics, “L6219—Stepper Motor Drive”, Datasheet, Dec. 1996, pp. 10.
SGS-Thomson Microelectronics, “PBL3717A—Stepper Motor Drive”, Datasheet, Apr. 1993, pp. 11.
Simonsen, Michael Ph.D., POC Testing, New Monitoring Strategies on Fast Growth Paths in European Healthcare Arenas, Biomedical Business & Technology, Jan. 2007, vol. 30, No. 1, pp. 1-36.
Smith, Joe, “Infusion Pump Informatics”, CatalyzeCare: Transforming Healthcare, as printed May 12, 2011, pp. 2.
Tang et al., “Linear Dimensionality Reduction Using Relevance Weighted LDA”, Pattern Recognition, 2005, vol. 38, pp. 485-493, http://staff.ustc.edu.cn/˜ketang/papers/TangSuganYaoQin_PR04.pdf.
Thomas et al., “Implementation of a Tight Glycaemic Control Protocol Using a Web-Based Insulin Dose Calculator”, Anaesthesia, 2005, vol. 60, pp. 1093-1100.
Van Den Berghe, M.D., Ph.D., et al., “Intensive Insulin Therapy in Critically III Patients”, The New England Journal of Medicine, Nov. 8, 2001, vol. 345, No. 19, pp. 1359-1367.
Van Den Berghe, M.D., Ph.D., et al., “Intensive Insulin Therapy in the Medical ICU”, The New England Journal of Medicine, Feb. 2, 2006, vol. 354, No. 5, pp. 449-461.
Westbrook et al., “Errors in the Administration of Intravenous Medications in Hospital and the Role of Correct Procedures and Nurse Experience”, BMJ Quality & Safety, 2011, vol. 20, pp. 1027-1034.
Zakariah et al., “Combination of Biphasic Transmittance Waveform with Blood Procalcitonin Levels for Diagnosis of Sepsis in Acutely III Patients”, Critical Care Medicine, 2008, vol. 36, No. 5, pp. 1507-1512.
International Search Report and Written Opinion received in PCT Application No. PCT/US2016/020355, dated Jul. 26, 2016 in 15 pages.
International Preliminary Report on Patentability and Written Opinion received in PCT Application No. PCT/US2016/020355, dated Sep. 14, 2017 in 12 pages.
Junda, Lin, “Global development trends of green bonds”, Jul. 10, 2018, pp. 9.
Notice of Opposition in European Patent Application No. 16759381.3 (Patent No. EP3285827), dated May 31, 2023 in 48 pages.
Response to Notice of Opposition in European Patent Application No. 16759381.3 (Patent No. EP3285827), dated Oct. 23, 2023 in 63 pages.
Response from the Opposer to patentee's submission in European Patent Application No. 16759381.3 (Patent No. EP3285827), dated Apr. 25, 2024 in 54 pages.
Summons to attend oral proceedings and preliminary opinion of Opposition Division submission in European Patent Application No. 16759381.3 (Patent No. EP3285827), dated May 23, 2024 in 18 pages.
Related Publications (1)
Number Date Country
20210146036 A1 May 2021 US
Provisional Applications (1)
Number Date Country
62127076 Mar 2015 US
Divisions (1)
Number Date Country
Parent 15057250 Mar 2016 US
Child 17106875 US